You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameDuloxetine
Accession NumberDB00476  (APRD00060)
TypeSmall Molecule
GroupsApproved
DescriptionDuloxetine (brand names Cymbalta, Yentreve, and in parts of Europe, Xeristar or Ariclaim) is a drug which primarily targets major depressive disorder (MDD), generalized anxiety disorder (GAD), pain related to diabetic peripheral neuropathy and in some countries stress urinary incontinence (SUI). It is manufactured and marketed by Eli Lilly and Company. Duloxetine has not yet been FDA approved for stress urinary incontinence or for fibromyalgia. Duloxetine is a selective SNRI (selective serotonin-norepinephrine reuptake inhibitor). Duloxetine is a systemic drug therapy which affects the body as a whole. Known also under the code name LY248686, it is a potent dual reuptake inhibitor of serotonin (5-hydroxytryptamine, 5-HT) and norepinephrine (NE), possessing comparable affinities in binding to NE- and 5-HT transporter sites. It is a less potent inhibitor of dopamine reuptake.
Structure
Thumb
Synonyms
(3S)-N-methyl-3-(1-naphthyloxy)-3-(2-thienyl)propan-1-amine
(S)-duloxetine
External Identifiers
  • LY 248686
  • LY-248686
  • LY248686
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Act DuloxetineCapsule, delayed release30 mgOralActavis Pharma CompanyNot applicableNot applicableCanada
Act DuloxetineCapsule, delayed release60 mgOralActavis Pharma CompanyNot applicableNot applicableCanada
AriclaimCapsule, delayed release30 mgOralEli Lilly Nederland B.V.2004-08-11Not applicableEu
AriclaimCapsule, delayed release60 mgOralEli Lilly Nederland B.V.2004-08-11Not applicableEu
AriclaimCapsule, delayed release30 mgOralEli Lilly Nederland B.V.2004-08-11Not applicableEu
AriclaimCapsule, delayed release30 mgOralEli Lilly Nederland B.V.2004-08-11Not applicableEu
AriclaimCapsule, delayed release60 mgOralEli Lilly Nederland B.V.2004-08-11Not applicableEu
Auro-duloxetineCapsule, delayed release30 mgOralAuro Pharma Inc2016-05-02Not applicableCanada
Auro-duloxetineCapsule, delayed release60 mgOralAuro Pharma Inc2016-05-02Not applicableCanada
CymbaltaCapsule, delayed release60 mg/1OralREMEDYREPACK INC.2010-12-23Not applicableUs
CymbaltaCapsule, delayed release60 mg/1Oralbryant ranch prepack2010-01-15Not applicableUs
CymbaltaCapsule, delayed release60 mgOralEli Lilly Nederland B.V.2004-12-17Not applicableEu
CymbaltaCapsule, delayed release20 mg/1OralCarilion Materials Management2004-08-24Not applicableUs
CymbaltaCapsule, delayed release30 mg/1OralRebel Distributors Corp.2004-08-24Not applicableUs
CymbaltaCapsule, delayed release20 mg/1OralPhysicians Total Care, Inc.2008-04-28Not applicableUs
CymbaltaCapsule, delayed release30 mgOralEli Lilly Canada Inc2008-01-18Not applicableCanada
CymbaltaCapsule, delayed release20 mg/1OralEli Lilly and Company2004-08-24Not applicableUs
CymbaltaCapsule, delayed release60 mgOralEli Lilly Nederland B.V.2004-12-17Not applicableEu
CymbaltaCapsule, delayed release30 mg/1OralUnit Dose Services2004-08-24Not applicableUs
CymbaltaCapsule, delayed release30 mg/1OralPd Rx Pharmaceuticals, Inc.2004-08-24Not applicableUs
CymbaltaCapsule, delayed release60 mg/1OralLake Erie Medical DBA Quality Care Products LLC2010-01-15Not applicableUs
CymbaltaCapsule, delayed release60 mg/1OralCardinal Health2004-08-24Not applicableUs
CymbaltaCapsule, delayed release60 mg/1OralA S Medication Solutions2010-01-15Not applicableUs
CymbaltaCapsule, delayed release30 mg/1OralLake Erie Medical Surgical & Supply DBA Quality Care Products LLC2011-07-14Not applicableUs
CymbaltaCapsule, delayed release30 mg/1Oralbryant ranch prepack2004-08-24Not applicableUs
CymbaltaCapsule, delayed release60 mgOralEli Lilly Nederland B.V.2004-12-17Not applicableEu
CymbaltaCapsule, delayed release60 mgOralEli Lilly Canada Inc2008-01-18Not applicableCanada
CymbaltaCapsule, delayed release30 mg/1OralEli Lilly and Company2004-08-24Not applicableUs
CymbaltaCapsule, delayed release60 mg/1OralRebel Distributors Corp.2004-08-24Not applicableUs
CymbaltaCapsule, delayed release30 mg/1OralPhysicians Total Care, Inc.2008-11-21Not applicableUs
CymbaltaCapsule, delayed release60 mgOralEli Lilly Nederland B.V.2004-12-17Not applicableEu
CymbaltaCapsule, delayed release60 mg/1OralUnit Dose Services2010-01-15Not applicableUs
CymbaltaCapsule, delayed release30 mg/1OralSTAT Rx USA LLC2004-08-24Not applicableUs
CymbaltaCapsule, delayed release60 mg/1OralSt Marys Medical Park Pharmacy2010-12-31Not applicableUs
CymbaltaCapsule, delayed release30 mgOralEli Lilly Nederland B.V.2004-12-17Not applicableEu
CymbaltaCapsule, delayed release60 mg/1OralClinical Solutions Wholesale2010-01-15Not applicableUs
CymbaltaCapsule, delayed release60 mgOralEli Lilly Nederland B.V.2004-12-17Not applicableEu
CymbaltaCapsule, delayed release30 mg/1OralA S Medication Solutions2004-08-24Not applicableUs
CymbaltaCapsule, delayed release60 mg/1OralLake Erie Medical Surgical & Supply DBA Quality Care Products LLC2011-07-14Not applicableUs
CymbaltaCapsule, delayed release60 mg/1OralEli Lilly and Company2010-01-15Not applicableUs
CymbaltaCapsule, delayed release20 mg/1OralRebel Distributors Corp2004-08-24Not applicableUs
CymbaltaCapsule, delayed release30 mg/1OralCardinal Health2004-08-24Not applicableUs
CymbaltaCapsule, delayed release60 mg/1OralH.J. Harkins Company, Inc.2010-01-15Not applicableUs
CymbaltaCapsule, delayed release30 mgOralEli Lilly Nederland B.V.2004-12-17Not applicableEu
CymbaltaCapsule, delayed release30 mg/1OralAphena Pharma Solutions Tennessee, Llc2004-08-24Not applicableUs
CymbaltaCapsule, delayed release30 mg/1OralSt Marys Medical Park Pharmacy2010-12-31Not applicableUs
CymbaltaCapsule, delayed release60 mgOralEli Lilly Nederland B.V.2004-12-17Not applicableEu
CymbaltaCapsule, delayed release30 mg/1OralCarilion Materials Management2004-08-24Not applicableUs
CymbaltaCapsule, delayed release30 mgOralEli Lilly Nederland B.V.2004-12-17Not applicableEu
CymbaltaCapsule, delayed release20 mg/1OralUnit Dose Services2004-08-24Not applicableUs
CymbaltaCapsule, delayed release60 mg/1OralPd Rx Pharmaceuticals, Inc.2010-01-15Not applicableUs
CymbaltaCapsule, delayed release30 mg/1OralREMEDYREPACK INC.2013-04-102016-04-05Us
CymbaltaCapsule, delayed release20 mg/1OralCardinal Health2004-08-24Not applicableUs
CymbaltaCapsule, delayed release60 mg/1OralPhysicians Total Care, Inc.2009-11-23Not applicableUs
Dom-duloxetineCapsule, delayed release30 mgOralDominion PharmacalNot applicableNot applicableCanada
Dom-duloxetineCapsule, delayed release60 mgOralDominion PharmacalNot applicableNot applicableCanada
DuloxetineCapsule, delayed release30 mgOralPro Doc Limitee2016-05-03Not applicableCanada
DuloxetineCapsule, delayed release60 mg/1OralCarilion Materials Management2014-01-24Not applicableUs
DuloxetineCapsule, delayed release60 mgOralAlembic Pharmaceuticals LimitedNot applicableNot applicableCanada
DuloxetineCapsule, delayed release60 mg/1OralPrasco Laboratories2014-01-242015-11-30Us
DuloxetineCapsule, delayed release60 mgOralPro Doc Limitee2016-05-03Not applicableCanada
DuloxetineCapsule, delayed release20 mg/1OralPrasco Laboratories2014-01-242016-11-30Us
DuloxetineCapsule, delayed release30 mgOralSivem Pharmaceuticals Ulc2016-05-05Not applicableCanada
DuloxetineCapsule, delayed release30 mg/1OralPrasco Laboratories2014-01-242016-09-30Us
DuloxetineCapsule, delayed release30 mgOralAlembic Pharmaceuticals LimitedNot applicableNot applicableCanada
DuloxetineCapsule, delayed release60 mgOralSivem Pharmaceuticals Ulc2016-05-05Not applicableCanada
Duloxetine DrCapsule, delayed release30 mgOralTeva Canada Limited2016-05-02Not applicableCanada
Duloxetine DrCapsule, delayed release60 mgOralTeva Canada Limited2016-05-02Not applicableCanada
Duloxetine LillyCapsule, delayed release30 mgOralEli Lilly Nederland B.V.2014-12-08Not applicableEu
Duloxetine LillyCapsule, delayed release60 mgOralEli Lilly Nederland B.V.2014-12-08Not applicableEu
Duloxetine LillyCapsule, delayed release30 mgOralEli Lilly Nederland B.V.2014-12-08Not applicableEu
Duloxetine LillyCapsule, delayed release60 mgOralEli Lilly Nederland B.V.2014-12-08Not applicableEu
Duloxetine LillyCapsule, delayed release60 mgOralEli Lilly Nederland B.V.2014-12-08Not applicableEu
Duloxetine LillyCapsule, delayed release60 mgOralEli Lilly Nederland B.V.2014-12-08Not applicableEu
Duloxetine LillyCapsule, delayed release30 mgOralEli Lilly Nederland B.V.2014-12-08Not applicableEu
Duloxetine LillyCapsule, delayed release60 mgOralEli Lilly Nederland B.V.2014-12-08Not applicableEu
Duloxetine LillyCapsule, delayed release60 mgOralEli Lilly Nederland B.V.2014-12-08Not applicableEu
Ipg-duloxetineCapsule, delayed release60 mgOralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Ipg-duloxetineCapsule, delayed release30 mgOralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Jamp-duloxetineCapsule, delayed release30 mgOralJamp Pharma Corporation2016-05-03Not applicableCanada
Jamp-duloxetineCapsule, delayed release60 mgOralJamp Pharma Corporation2016-05-03Not applicableCanada
Mar-duloxetineCapsule, delayed release60 mgOralMarcan Pharmaceuticals Inc2016-05-10Not applicableCanada
Mar-duloxetineCapsule, delayed release30 mgOralMarcan Pharmaceuticals Inc2016-05-10Not applicableCanada
Mint-duloxetineCapsule, delayed release30 mgOralMint Pharmaceuticals Inc2016-05-02Not applicableCanada
Mint-duloxetineCapsule, delayed release60 mgOralMint Pharmaceuticals Inc2016-05-02Not applicableCanada
Mylan-duloxetineCapsule, delayed release60 mgOralMylan Pharmaceuticals UlcNot applicableNot applicableCanada
Mylan-duloxetineCapsule, delayed release30 mgOralMylan Pharmaceuticals UlcNot applicableNot applicableCanada
PMS-duloxetineCapsule, delayed release30 mgOralPharmascience Inc2016-05-02Not applicableCanada
PMS-duloxetineCapsule, delayed release60 mgOralPharmascience Inc2016-05-02Not applicableCanada
Ran-duloxetineCapsule, delayed release30 mgOralRanbaxy Pharmaceuticals Canada Inc.2016-05-02Not applicableCanada
Ran-duloxetineCapsule, delayed release60 mgOralRanbaxy Pharmaceuticals Canada Inc.2016-05-02Not applicableCanada
Riva-duloxetineCapsule, delayed release30 mgOralLaboratoire Riva Inc2016-05-02Not applicableCanada
Riva-duloxetineCapsule, delayed release60 mgOralLaboratoire Riva Inc2016-05-12Not applicableCanada
Sandoz DuloxetineCapsule, delayed release30 mgOralSandoz Canada Incorporated2016-05-02Not applicableCanada
Sandoz DuloxetineCapsule, delayed release60 mgOralSandoz Canada Incorporated2016-05-02Not applicableCanada
Taro-duloxetineCapsule, delayed release30 mgOralTaro Pharmaceuticals IncNot applicableNot applicableCanada
Taro-duloxetineCapsule, delayed release60 mgOralTaro Pharmaceuticals IncNot applicableNot applicableCanada
Teva-duloxetine DrCapsule, delayed release30 mgOralTeva Canada LimitedNot applicableNot applicableCanada
Teva-duloxetine DrCapsule, delayed release60 mgOralTeva Canada LimitedNot applicableNot applicableCanada
XeristarCapsule, delayed release60 mgOralEli Lilly Nederland B.V.2004-12-17Not applicableEu
XeristarCapsule, delayed release30 mgOralEli Lilly Nederland B.V.2004-12-17Not applicableEu
XeristarCapsule, delayed release60 mgOralEli Lilly Nederland B.V.2004-12-17Not applicableEu
XeristarCapsule, delayed release60 mgOralEli Lilly Nederland B.V.2004-12-17Not applicableEu
XeristarCapsule, delayed release60 mgOralEli Lilly Nederland B.V.2004-12-17Not applicableEu
XeristarCapsule, delayed release60 mgOralEli Lilly Nederland B.V.2004-12-17Not applicableEu
XeristarCapsule, delayed release60 mgOralEli Lilly Nederland B.V.2004-12-17Not applicableEu
XeristarCapsule, delayed release30 mgOralEli Lilly Nederland B.V.2004-12-17Not applicableEu
YentreveCapsule, delayed release20 mgOralEli Lilly Nederland B.V.2004-08-11Not applicableEu
YentreveCapsule, delayed release40 mgOralEli Lilly Nederland B.V.2004-08-11Not applicableEu
YentreveCapsule, delayed release40 mgOralEli Lilly Nederland B.V.2004-08-11Not applicableEu
YentreveCapsule, delayed release40 mgOralEli Lilly Nederland B.V.2004-08-11Not applicableEu
YentreveCapsule, delayed release40 mgOralEli Lilly Nederland B.V.2004-08-11Not applicableEu
YentreveCapsule, delayed release20 mgOralEli Lilly Nederland B.V.2004-08-11Not applicableEu
YentreveCapsule, delayed release40 mgOralEli Lilly Nederland B.V.2004-08-11Not applicableEu
YentreveCapsule, delayed release20 mgOralEli Lilly Nederland B.V.2004-08-11Not applicableEu
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-duloxetineCapsule, delayed release30 mgOralApotex Inc2016-05-03Not applicableCanada
Apo-duloxetineCapsule, delayed release60 mgOralApotex Inc2016-05-03Not applicableCanada
DuloxetineCapsule, delayed release20 mg/1OralREMEDYREPACK INC.2016-05-06Not applicableUs
DuloxetineCapsule, delayed release30 mg/1OralBlue Point Laboratories2014-03-14Not applicableUs
DuloxetineCapsule, delayed release60 mg/1OralCardinal Health2013-12-11Not applicableUs
DuloxetineCapsule, delayed release20 mg/1OralCadila Healthcare Limited2014-05-27Not applicableUs
DuloxetineCapsule, delayed release60 mg/1OralAvera Mc Kennan Hospital2015-03-09Not applicableUs
DuloxetineCapsule, delayed release30 mg/1OralREMEDYREPACK INC.2014-04-24Not applicableUs
DuloxetineCapsule, delayed release60 mg/1OralAurobindo Pharma Limited2013-12-11Not applicableUs
DuloxetineCapsule, delayed release30 mg/1OralPreferred Pharmaceuticals Inc.2016-06-21Not applicableUs
DuloxetineCapsule, delayed release20 mg/1OralKAISER FOUNDATION HOSPITALS2014-01-20Not applicableUs
DuloxetineCapsule, delayed release20 mg/1OralREMEDYREPACK INC.2014-01-302016-04-05Us
DuloxetineCapsule, delayed release60 mg/1Oralbryant ranch prepack2013-12-11Not applicableUs
DuloxetineCapsule, delayed release60 mg/1OralAscend Laboratories, LLC2012-05-01Not applicableUs
DuloxetineCapsule, delayed release30 mg/1OralPrasco Laboratories2013-12-11Not applicableUs
DuloxetineCapsule, delayed release30 mg/1OralREMEDYREPACK INC.2016-01-26Not applicableUs
DuloxetineCapsule, delayed release30 mg/1OralCitron Pharma LLC2013-12-11Not applicableUs
DuloxetineCapsule, delayed release30 mg/1OralCamber Pharmaceuticals, Inc.2016-08-11Not applicableUs
DuloxetineCapsule, delayed release30 mg/1OralLupin Pharmaceuticals, Inc.2013-12-11Not applicableUs
DuloxetineCapsule, delayed release20 mg/1OralCadila Healthcare Limited2014-02-15Not applicableUs
DuloxetineCapsule, delayed release60 mg/1OralPreferred Pharmaceuticals, Inc.2014-11-25Not applicableUs
DuloxetineCapsule, delayed release20 mg/1OralCipla USA Inc.2015-12-05Not applicableUs
DuloxetineCapsule, delayed release30 mg/1OralA S Medication Solutions2013-12-11Not applicableUs
DuloxetineCapsule, delayed release pellets30 mg/1OralMedsource Pharmaceuticals2014-06-18Not applicableUs
DuloxetineCapsule, delayed release30 mg/1OralCardinal Health2013-12-23Not applicableUs
DuloxetineCapsule, delayed release20 mg/1OralREMEDYREPACK INC.2016-08-16Not applicableUs
DuloxetineCapsule, delayed release20 mg/1OralSun Pharma Global FZE2013-12-11Not applicableUs
DuloxetineCapsule, delayed release60 mg/1OralBlue Point Laboratories2014-03-14Not applicableUs
DuloxetineCapsule, delayed release30 mg/1OralCadila Healthcare Limited2014-05-27Not applicableUs
DuloxetineCapsule, delayed release20 mg/1OralAmerican Health Packaging2013-12-23Not applicableUs
DuloxetineCapsule, delayed release20 mg/1OralTeva Pharmaceuticals Usa, Inc.2013-12-11Not applicableUs
DuloxetineCapsule, delayed release20 mg/1OralZydus Pharmaceuticals (USA) Inc.2014-05-27Not applicableUs
DuloxetineCapsule, delayed release20 mg/1OralActavis Pharma, Inc.2013-12-17Not applicableUs
DuloxetineCapsule, delayed release20 mg/1OralAv Kare, Inc.2014-07-082016-10-13Us
DuloxetineCapsule, delayed release pellets20 mg/1OralDr. Reddy's Laboratories Limited2014-06-18Not applicableUs
DuloxetineCapsule, delayed release60 mg/1OralPrasco Laboratories2013-12-11Not applicableUs
DuloxetineCapsule, delayed release30 mg/1OralProficient Rx LP2013-12-11Not applicableUs
DuloxetineCapsule, delayed release60 mg/1OralCitron Pharma LLC2013-12-11Not applicableUs
DuloxetineCapsule, delayed release60 mg/1OralCamber Pharmaceuticals, Inc.2016-08-11Not applicableUs
DuloxetineCapsule, delayed release60 mg/1OralLupin Pharmaceuticals, Inc.2013-12-11Not applicableUs
DuloxetineCapsule, delayed release20 mg/1OralTrigen Laboratories, LLC2014-08-19Not applicableUs
DuloxetineCapsule, delayed release pellets60 mg/1OralMedsource Pharmaceuticals2014-06-18Not applicableUs
DuloxetineCapsule, delayed release20 mg/1OralCardinal Health2013-12-11Not applicableUs
DuloxetineCapsule, delayed release30 mg/1OralCadila Healthcare Limited2014-02-15Not applicableUs
DuloxetineCapsule, delayed release pellets30 mg/1OralPreferred Pharmaceuticals, Inc.2014-11-18Not applicableUs
DuloxetineCapsule, delayed release30 mg/1OralCipla USA Inc.2015-12-05Not applicableUs
DuloxetineCapsule, delayed release60 mg/1OralCadila Healthcare Limited2014-05-27Not applicableUs
DuloxetineCapsule, delayed release30 mg/1OralA S Medication Solutions2013-12-11Not applicableUs
DuloxetineCapsule, delayed release60 mg/1OralCardinal Health2013-12-23Not applicableUs
DuloxetineCapsule, delayed release30 mg/1OralREMEDYREPACK INC.2016-10-11Not applicableUs
DuloxetineCapsule, delayed release30 mg/1OralSun Pharma Global FZE2013-12-11Not applicableUs
DuloxetineCapsule, delayed release60 mg/1OralDIRECT RX2014-01-01Not applicableUs
DuloxetineCapsule, delayed release pellets30 mg/1OralDr. Reddy's Laboratories Limited2014-06-18Not applicableUs
DuloxetineCapsule, delayed release30 mg/1OralAmerican Health Packaging2013-12-23Not applicableUs
DuloxetineCapsule, delayed release30 mg/1OralTeva Pharmaceuticals Usa, Inc.2013-12-11Not applicableUs
DuloxetineCapsule, delayed release30 mg/1OralZydus Pharmaceuticals (USA) Inc.2014-05-27Not applicableUs
DuloxetineCapsule, delayed release30 mg/1OralUnit Dose Services2013-12-11Not applicableUs
DuloxetineCapsule, delayed release30 mg/1OralActavis Pharma, Inc.2013-12-17Not applicableUs
DuloxetineCapsule, delayed release30 mg/1OralAv Kare, Inc.2014-07-082016-10-13Us
DuloxetineCapsule, delayed release30 mg/1OralTrigen Laboratories, LLC2014-08-19Not applicableUs
DuloxetineCapsule, delayed release20 mg/1OralAscend Laboratories, LLC2012-05-01Not applicableUs
DuloxetineCapsule, delayed release60 mg/1OralProficient Rx LP2013-12-11Not applicableUs
DuloxetineCapsule, delayed release20 mg/1OralAurobindo Pharma Limited2013-12-11Not applicableUs
DuloxetineCapsule, delayed release40 mg/1OralLupin Pharmaceuticals, Inc.2015-05-25Not applicableUs
DuloxetineCapsule, delayed release20 mg/1OralBlue Point Laboratories2014-03-14Not applicableUs
DuloxetineCapsule, delayed release30 mg/1OralCardinal Health2013-12-11Not applicableUs
DuloxetineCapsule, delayed release60 mg/1OralCadila Healthcare Limited2014-02-15Not applicableUs
DuloxetineCapsule, delayed release60 mg/1OralCipla USA Inc.2015-12-05Not applicableUs
DuloxetineCapsule, delayed release30 mg/1OralA S Medication Solutions2013-12-11Not applicableUs
DuloxetineCapsule, delayed release20 mg/1OralPrasco Laboratories2013-12-11Not applicableUs
DuloxetineCapsule, delayed release30 mg/1OralAvera Mc Kennan Hospital2015-03-02Not applicableUs
DuloxetineCapsule, delayed release20 mg/1OralCitron Pharma LLC2013-12-11Not applicableUs
DuloxetineCapsule, delayed release20 mg/1OralCamber Pharmaceuticals, Inc.2016-08-11Not applicableUs
DuloxetineCapsule, delayed release60 mg/1OralSun Pharma Global FZE2013-12-11Not applicableUs
DuloxetineCapsule, delayed release20 mg/1OralLupin Pharmaceuticals, Inc.2013-12-11Not applicableUs
DuloxetineCapsule, delayed release pellets60 mg/1OralDr. Reddy's Laboratories Limited2014-06-18Not applicableUs
DuloxetineCapsule, delayed release60 mg/1OralTYA Pharmaceuticals2013-12-11Not applicableUs
DuloxetineCapsule, delayed release60 mg/1OralAmerican Health Packaging2013-12-23Not applicableUs
DuloxetineCapsule, delayed release60 mg/1OralTeva Pharmaceuticals Usa, Inc.2013-12-11Not applicableUs
DuloxetineCapsule, delayed release60 mg/1OralZydus Pharmaceuticals (USA) Inc.2014-05-27Not applicableUs
DuloxetineCapsule, delayed release60 mg/1OralLake Erie Medical DBA Quality Care Products LLC2013-12-11Not applicableUs
DuloxetineCapsule, delayed release60 mg/1OralA S Medication Solutions2013-12-112016-10-26Us
DuloxetineCapsule, delayed release60 mg/1OralActavis Pharma, Inc.2013-12-17Not applicableUs
DuloxetineCapsule, delayed release60 mg/1OralAv Kare, Inc.2014-07-082016-10-13Us
DuloxetineCapsule, delayed release60 mg/1OralTrigen Laboratories, LLC2014-08-19Not applicableUs
DuloxetineCapsule, delayed release30 mg/1OralREMEDYREPACK INC.2014-01-302016-04-05Us
DuloxetineCapsule, delayed release30 mg/1Oralbryant ranch prepack2013-12-11Not applicableUs
DuloxetineCapsule, delayed release30 mg/1OralAscend Laboratories, LLC2012-05-01Not applicableUs
DuloxetineCapsule, delayed release30 mg/1OralAurobindo Pharma Limited2013-12-11Not applicableUs
Duloxetine Delayed-releaseCapsule, delayed release pellets30 mg/1OralREMEDYREPACK INC.2016-03-14Not applicableUs
Duloxetine Delayed-releaseCapsule, delayed release pellets60 mg/1OralA S Medication Solutions2014-06-11Not applicableUs
Duloxetine Delayed-releaseCapsule, delayed release pellets30 mg/1OralAphena Pharma Solutions Tennessee, Llc2014-06-11Not applicableUs
Duloxetine Delayed-releaseCapsule, delayed release pellets30 mg/1OralBlenheim Pharmacal, Inc.2016-04-01Not applicableUs
Duloxetine Delayed-releaseCapsule, delayed release pellets20 mg/1OralBreckenridge Pharmaceutical, Inc.2014-06-11Not applicableUs
Duloxetine Delayed-releaseCapsule, delayed release pellets60 mg/1OralA S Medication Solutions2014-06-11Not applicableUs
Duloxetine Delayed-releaseCapsule, delayed release pellets20 mg/1OralGolden State Medical Supply, Inc.2014-06-11Not applicableUs
Duloxetine Delayed-releaseCapsule, delayed release pellets30 mg/1OralTYA Pharmaceuticals2014-06-11Not applicableUs
Duloxetine Delayed-releaseCapsule, delayed release pellets60 mg/1OralPreferred Pharmaceuticals Inc.2016-09-30Not applicableUs
Duloxetine Delayed-releaseCapsule, delayed release pellets30 mg/1OralBreckenridge Pharmaceutical, Inc.2014-06-11Not applicableUs
Duloxetine Delayed-releaseCapsule, delayed release pellets20 mg/1OralProficient Rx LP2014-06-11Not applicableUs
Duloxetine Delayed-releaseCapsule, delayed release pellets30 mg/1OralGolden State Medical Supply, Inc.2014-06-11Not applicableUs
Duloxetine Delayed-releaseCapsule, delayed release pellets60 mg/1OralBreckenridge Pharmaceutical, Inc.2014-06-11Not applicableUs
Duloxetine Delayed-releaseCapsule, delayed release pellets60 mg/1OralAphena Pharma Solutions Tennessee, Llc2014-06-11Not applicableUs
Duloxetine Delayed-releaseCapsule, delayed release pellets60 mg/1OralProficient Rx LP2014-06-11Not applicableUs
Duloxetine Delayed-releaseCapsule, delayed release pellets30 mg/1OralPreferred Pharmaceuticals, Inc.2015-03-23Not applicableUs
Duloxetine Delayed-releaseCapsule, delayed release pellets60 mg/1OralREMEDYREPACK INC.2016-05-10Not applicableUs
Duloxetine Delayed-releaseCapsule, delayed release pellets60 mg/1OralGolden State Medical Supply, Inc.2014-06-11Not applicableUs
Duloxetine Delayed-releaseCapsule, delayed release pellets30 mg/1OralProficient Rx LP2014-06-11Not applicableUs
Duloxetine Delayed-releaseCapsule, delayed release pellets60 mg/1OralBlenheim Pharmacal, Inc.2016-04-01Not applicableUs
Duloxetine Delayed-releaseCapsule, delayed release pellets20 mg/1OralAphena Pharma Solutions Tennessee, Llc2014-06-11Not applicableUs
Duloxetine Delayed-releaseCapsule, delayed release pellets20 mg/1OralPreferred Pharmaceuticals Inc.2016-05-04Not applicableUs
Duloxetine HydrochlorideCapsule, delayed release30 mg/1OralMajor Pharmaceuticals2013-12-11Not applicableUs
Duloxetine HydrochlorideCapsule, delayed release60 mg/1OralApotex Corp.2014-06-13Not applicableUs
Duloxetine HydrochlorideCapsule, delayed release30 mg/1OralProficient Rx LP2014-06-13Not applicableUs
Duloxetine HydrochlorideCapsule, delayed release20 mg/1OralProficient Rx LP2014-06-13Not applicableUs
Duloxetine HydrochlorideCapsule, delayed release30 mg/1OralPreferred Pharmaceuticals, Inc.2014-08-20Not applicableUs
Duloxetine HydrochlorideCapsule, delayed release60 mg/1OralTorrent Pharmaceuticals Limited2013-12-11Not applicableUs
Duloxetine HydrochlorideCapsule, delayed release30 mg/1OralCardinal Health2013-12-11Not applicableUs
Duloxetine HydrochlorideCapsule, delayed release20 mg/1OralMajor Pharmaceuticals2014-06-13Not applicableUs
Duloxetine HydrochlorideCapsule, delayed release60 mg/1OralLake Erie Medical DBA Quality Care Products LLC2014-06-13Not applicableUs
Duloxetine HydrochlorideCapsule, delayed release30 mg/1OralUnit Dose Services2014-06-13Not applicableUs
Duloxetine HydrochlorideCapsule, delayed release30 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2013-12-11Not applicableUs
Duloxetine HydrochlorideCapsule, delayed release30 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2014-06-13Not applicableUs
Duloxetine HydrochlorideCapsule, delayed release60 mg/1OralMajor Pharmaceuticals2013-12-11Not applicableUs
Duloxetine HydrochlorideCapsule, delayed release60 mg/1OralA S Medication Solutions2013-12-11Not applicableUs
Duloxetine HydrochlorideCapsule, delayed release60 mg/1OralApotex Corp.2014-06-132016-11-22Us
Duloxetine HydrochlorideCapsule, delayed release60 mg/1OralProficient Rx LP2014-06-13Not applicableUs
Duloxetine HydrochlorideCapsule, delayed release20 mg/1OralPreferred Pharmaceuticals, Inc.2014-08-20Not applicableUs
Duloxetine HydrochlorideCapsule, delayed release60 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2013-12-11Not applicableUs
Duloxetine HydrochlorideCapsule, delayed release30 mg/1OralMajor Pharmaceuticals2014-06-13Not applicableUs
Duloxetine HydrochlorideCapsule, delayed release20 mg/1OralLake Erie Medical DBA Quality Care Products LLC2014-08-20Not applicableUs
Duloxetine HydrochlorideCapsule, delayed release pellets30 mg/1OralDIRECT RX2014-01-01Not applicableUs
Duloxetine HydrochlorideCapsule, delayed release60 mg/1OralUnit Dose Services2014-06-13Not applicableUs
Duloxetine HydrochlorideCapsule, delayed release60 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2014-06-13Not applicableUs
Duloxetine HydrochlorideCapsule, delayed release20 mg/1OralTorrent Pharmaceuticals Limited2013-12-11Not applicableUs
Duloxetine HydrochlorideCapsule, delayed release30 mg/1OralUnit Dose Services2013-12-11Not applicableUs
Duloxetine HydrochlorideCapsule, delayed release30 mg/1OralTYA Pharmaceuticals2013-12-11Not applicableUs
Duloxetine HydrochlorideCapsule, delayed release30 mg/1OralA S Medication Solutions2013-12-11Not applicableUs
Duloxetine HydrochlorideCapsule, delayed release pellets60 mg/1OralDIRECT RX2014-01-01Not applicableUs
Duloxetine HydrochlorideCapsule, delayed release60 mg/1OralProficient Rx LP2013-12-11Not applicableUs
Duloxetine HydrochlorideCapsule, delayed release20 mg/1OralApotex Corp.2014-06-13Not applicableUs
Duloxetine HydrochlorideCapsule, delayed release20 mg/1OralMajor Pharmaceuticals2013-12-11Not applicableUs
Duloxetine HydrochlorideCapsule, delayed release60 mg/1OralMajor Pharmaceuticals2014-06-13Not applicableUs
Duloxetine HydrochlorideCapsule, delayed release30 mg/1OralTorrent Pharmaceuticals Limited2013-12-11Not applicableUs
Duloxetine HydrochlorideCapsule, delayed release60 mg/1OralUnit Dose Services2013-12-11Not applicableUs
Duloxetine HydrochlorideCapsule, delayed release20 mg/1OralUnit Dose Services2014-06-13Not applicableUs
Duloxetine HydrochlorideCapsule, delayed release30 mg/1OralApotex Corp.2014-06-13Not applicableUs
Duloxetine Hydrochloride 20 mgCapsule, delayed release20 mg/1OralAlembic Pharmaceuticals Limited2014-06-09Not applicableUs
Duloxetine Hydrochloride 30 mgCapsule, delayed release30 mg/1OralAlembic Pharmaceuticals Limited2014-06-09Not applicableUs
Duloxetine Hydrochloride 60 mgCapsule, delayed release60 mg/1OralAlembic Pharmaceuticals Limited2014-06-09Not applicableUs
Duloxetine MylanCapsule, delayed release30 mgOralGenerics (Uk) Limited2015-06-19Not applicableEu
Duloxetine MylanCapsule, delayed release60 mgOralGenerics (Uk) Limited2015-06-19Not applicableEu
Duloxetine MylanCapsule, delayed release60 mgOralGenerics (Uk) Limited2015-06-19Not applicableEu
Duloxetine MylanCapsule, delayed release60 mgOralGenerics (Uk) Limited2015-06-19Not applicableEu
Duloxetine MylanCapsule, delayed release30 mgOralGenerics (Uk) Limited2015-06-19Not applicableEu
Duloxetine MylanCapsule, delayed release30 mgOralGenerics (Uk) Limited2015-06-19Not applicableEu
Duloxetine MylanCapsule, delayed release30 mgOralGenerics (Uk) Limited2015-06-19Not applicableEu
Duloxetine MylanCapsule, delayed release30 mgOralGenerics (Uk) Limited2015-06-19Not applicableEu
Duloxetine MylanCapsule, delayed release60 mgOralGenerics (Uk) Limited2015-06-19Not applicableEu
Duloxetine MylanCapsule, delayed release60 mgOralGenerics (Uk) Limited2015-06-19Not applicableEu
Duloxetine MylanCapsule, delayed release60 mgOralGenerics (Uk) Limited2015-06-19Not applicableEu
Duloxetine MylanCapsule, delayed release30 mgOralGenerics (Uk) Limited2015-06-19Not applicableEu
Duloxetine MylanCapsule, delayed release30 mgOralGenerics (Uk) Limited2015-06-19Not applicableEu
Duloxetine MylanCapsule, delayed release60 mgOralGenerics (Uk) Limited2015-06-19Not applicableEu
Duloxetine MylanCapsule, delayed release60 mgOralGenerics (Uk) Limited2015-06-19Not applicableEu
Duloxetine MylanCapsule, delayed release30 mgOralGenerics (Uk) Limited2015-06-19Not applicableEu
Duloxetine MylanCapsule, delayed release30 mgOralGenerics (Uk) Limited2015-06-19Not applicableEu
Duloxetine MylanCapsule, delayed release30 mgOralGenerics (Uk) Limited2015-06-19Not applicableEu
Duloxetine MylanCapsule, delayed release60 mgOralGenerics (Uk) Limited2015-06-19Not applicableEu
Duloxetine MylanCapsule, delayed release60 mgOralGenerics (Uk) Limited2015-06-19Not applicableEu
Duloxetine MylanCapsule, delayed release30 mgOralGenerics (Uk) Limited2015-06-19Not applicableEu
Duloxetine MylanCapsule, delayed release30 mgOralGenerics (Uk) Limited2015-06-19Not applicableEu
Duloxetine MylanCapsule, delayed release60 mgOralGenerics (Uk) Limited2015-06-19Not applicableEu
Duloxetine MylanCapsule, delayed release60 mgOralGenerics (Uk) Limited2015-06-19Not applicableEu
Duloxetine MylanCapsule, delayed release60 mgOralGenerics (Uk) Limited2015-06-19Not applicableEu
Duloxetine MylanCapsule, delayed release30 mgOralGenerics (Uk) Limited2015-06-19Not applicableEu
Duloxetine MylanCapsule, delayed release30 mgOralGenerics (Uk) Limited2015-06-19Not applicableEu
Duloxetine MylanCapsule, delayed release60 mgOralGenerics (Uk) Limited2015-06-19Not applicableEu
Duloxetine MylanCapsule, delayed release60 mgOralGenerics (Uk) Limited2015-06-19Not applicableEu
Duloxetine MylanCapsule, delayed release30 mgOralGenerics (Uk) Limited2015-06-19Not applicableEu
Duloxetine MylanCapsule, delayed release30 mgOralGenerics (Uk) Limited2015-06-19Not applicableEu
Duloxetine MylanCapsule, delayed release30 mgOralGenerics (Uk) Limited2015-06-19Not applicableEu
Duloxetine MylanCapsule, delayed release60 mgOralGenerics (Uk) Limited2015-06-19Not applicableEu
Duloxetine MylanCapsule, delayed release60 mgOralGenerics (Uk) Limited2015-06-19Not applicableEu
Duloxetine MylanCapsule, delayed release60 mgOralGenerics (Uk) Limited2015-06-19Not applicableEu
Duloxetine MylanCapsule, delayed release30 mgOralGenerics (Uk) Limited2015-06-19Not applicableEu
Duloxetine ZentivaCapsule, delayed release60 mgOralZentiva, K.S.2015-08-20Not applicableEu
Duloxetine ZentivaCapsule, delayed release30 mgOralZentiva, K.S.2015-08-20Not applicableEu
Duloxetine ZentivaCapsule, delayed release60 mgOralZentiva, K.S.2015-08-20Not applicableEu
Duloxetine ZentivaCapsule, delayed release30 mgOralZentiva, K.S.2015-08-20Not applicableEu
Duloxetine ZentivaCapsule, delayed release60 mgOralZentiva, K.S.2015-08-20Not applicableEu
Duloxetine ZentivaCapsule, delayed release30 mgOralZentiva, K.S.2015-08-20Not applicableEu
Duloxetine ZentivaCapsule, delayed release60 mgOralZentiva, K.S.2015-08-20Not applicableEu
IrenkaCapsule, delayed release40 mg/1OralLupin Pharma2015-06-01Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AriclaimNot Available
DulaneNot Available
DuzelaNot Available
XeristarNot Available
YentreveNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Duloxetine hydrochloride
136434-34-9
Thumb
  • InChI Key: BFFSMCNJSOPUAY-LMOVPXPDSA-N
  • Monoisotopic Mass: 333.0954131
  • Average Mass: 333.87
DBSALT000378
Categories
UNIIO5TNM5N07U
CAS number116539-59-4
WeightAverage: 297.415
Monoisotopic: 297.118734925
Chemical FormulaC18H19NOS
InChI KeyZEUITGRIYCTCEM-KRWDZBQOSA-N
InChI
InChI=1S/C18H19NOS/c1-19-12-11-17(18-10-5-13-21-18)20-16-9-4-7-14-6-2-3-8-15(14)16/h2-10,13,17,19H,11-12H2,1H3/t17-/m0/s1
IUPAC Name
methyl[(3S)-3-(naphthalen-1-yloxy)-3-(thiophen-2-yl)propyl]amine
SMILES
CNCC[[email protected]](OC1=CC=CC2=CC=CC=C12)C1=CC=CS1
Pharmacology
IndicationFor the acute and maintenance treatment of major depressive disorder (MDD), as well as acute management of generalized anxiety disorder. Also used for the management of neuropathic pain associated with diabetic peripheral neuropathy, and fibromyalgia. Has been used in the management of moderate to severe stress urinary incontinence (SUI) in women.
Structured Indications
PharmacodynamicsDuloxetine is in a class of medications called selective serotonin and norepinephrine reuptake inhibitors (SSNRIs) and primarily targets major depressive disorders (MDD) and stress urinary incontinence (SUI). Duloxetine is also used to treat pain and tingling caused by diabetic neuropathy (damage to nerves that can develop in people who have diabetes). Known also as LY248686, it is a potent dual inhibitor of serotonin (5-hydroxytryptamine, 5-HT) and norepinephrine (NE) reuptake, possessing comparable affinities in binding to NE and 5-HT transport sites. Interestingly, its behavior contrasts to most other dual-reuptake inhibitors. Furthermore, duloxentine lacks affinity for monoamine receptors within the central nervous system.
Mechanism of actionDuloxetine is a potent inhibitor of neuronal serotonin and norepinephrine reuptake and a less potent inhibitor of dopamine reuptake. Duloxetine has no significant affinity for dopaminergic, adrenergic, cholinergic, histaminergic, opioid, glutamate, and GABA receptors. The antidepressant and pain inhibitory actions of duloxetine are believed to be related to its potentiation of serotonergic and noradrenergic activity in the CNS. The mechanism of action of duloxetine in SUI has not been determined, but is thought to be associated with the potentiation of serotonin and norepinephrine activity in the spinal cord, which increases urethral closure forces and thereby reduces involuntary urine loss.
TargetKindPharmacological actionActionsOrganismUniProt ID
Sodium-dependent serotonin transporterProteinyes
inhibitor
HumanP31645 details
Sodium-dependent noradrenaline transporterProteinyes
inhibitor
HumanP23975 details
Sodium-dependent dopamine transporterProteinunknown
inhibitor
HumanQ01959 details
Related Articles
AbsorptionOrally administered duloxetine hydrochloride is well absorbed.
Volume of distribution
  • 1640 L
Protein bindingProtein binding is greater than 90%.
Metabolism

The major biotransformation pathways for duloxetine involve oxidation of the naphthyl ring followed by conjugation and further oxidation. Both CYP2D6 and CYP1A2 catalyze the oxidation of the naphthyl ring in vitro. Metabolites found in plasma include 4-hydroxy duloxetine glucuronide and 5-hydroxy, 6-methoxy duloxetine sulfate. The major circulating metabolites have not been shown to contribute significantly to the pharmacologic activity of duloxetine.

SubstrateEnzymesProduct
Duloxetine
Not Available
4-hydroxy duloxetine glucuronideDetails
Duloxetine
Not Available
5-hydroxy, 6-methoxy duloxetine sulfateDetails
Route of eliminationMany additional metabolites have been identified in urine, some representing only minor pathways of elimination. Most (about 70%) of the duloxetine dose appears in the urine as metabolites of duloxetine; about 20% is excreted in the feces.
Half life12 hours (range 8-17 hours)
ClearanceNot Available
ToxicityOral, rat LD50: 491 mg/kg for males and 279 mg/kg for females. Symptoms of overdose include tremors, convulsions, reduced activity, slow pupillary response, intermittent tremors, and rigidity.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,1,1,2 TetrafluoroethaneThe risk or severity of adverse effects can be increased when 1,1,1,2 Tetrafluoroethane is combined with Duloxetine.Investigational
4-MethoxyamphetamineThe metabolism of 4-Methoxyamphetamine can be decreased when combined with Duloxetine.Experimental, Illicit
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Duloxetine.Experimental
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the serotonergic activities of Duloxetine.Experimental
AbirateroneThe serum concentration of Duloxetine can be increased when it is combined with Abiraterone.Approved
AcarboseDuloxetine may increase the hypoglycemic activities of Acarbose.Approved, Investigational
AcebutololAcebutolol may increase the orthostatic hypotensive activities of Duloxetine.Approved
AcenocoumarolDuloxetine may increase the anticoagulant activities of Acenocoumarol.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Aceprometazine.Approved
AcetaminophenThe metabolism of Acetaminophen can be decreased when combined with Duloxetine.Approved
AcetazolamideAcetazolamide may increase the orthostatic hypotensive activities of Duloxetine.Approved, Vet Approved
AcetophenazineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Acetophenazine.Approved
AcetylcholineThe metabolism of Acetylcholine can be decreased when combined with Duloxetine.Approved
Acetylsalicylic acidDuloxetine may increase the antiplatelet activities of Acetylsalicylic acid.Approved, Vet Approved
adipiplonThe risk or severity of adverse effects can be increased when adipiplon is combined with Duloxetine.Investigational
AdrafinilDuloxetine may increase the tachycardic activities of Adrafinil.Withdrawn
AgmatineDuloxetine may decrease the antihypertensive activities of Agmatine.Experimental, Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Duloxetine.Approved, Investigational
AjmalineThe metabolism of Ajmaline can be decreased when combined with Duloxetine.Approved
AlbiglutideDuloxetine may increase the hypoglycemic activities of Albiglutide.Approved
AldesleukinAldesleukin may increase the orthostatic hypotensive activities of Duloxetine.Approved
AlfaxaloneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Duloxetine.Vet Approved
AlfentanilAlfentanil may increase the serotonergic activities of Duloxetine.Approved, Illicit
AliskirenAliskiren may increase the orthostatic hypotensive activities of Duloxetine.Approved, Investigational
AlmotriptanThe risk or severity of adverse effects can be increased when Duloxetine is combined with Almotriptan.Approved, Investigational
AlogliptinThe metabolism of Alogliptin can be decreased when combined with Duloxetine.Approved
AlphacetylmethadolAlphacetylmethadol may increase the serotonergic activities of Duloxetine.Experimental, Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Duloxetine.Approved, Illicit, Investigational
AlprenololThe metabolism of Alprenolol can be decreased when combined with Duloxetine.Approved, Withdrawn
AmifostineAmifostine may increase the orthostatic hypotensive activities of Duloxetine.Approved, Investigational
AmilorideAmiloride may increase the orthostatic hypotensive activities of Duloxetine.Approved
AmineptineDuloxetine may increase the serotonergic activities of Amineptine.Illicit, Withdrawn
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Duloxetine.Approved, Withdrawn
AmiodaroneAmiodarone may increase the orthostatic hypotensive activities of Duloxetine.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Duloxetine is combined with Amisulpride.Approved, Investigational
AmitrazDuloxetine may increase the tachycardic activities of Amitraz.Vet Approved
AmitriptylineDuloxetine may increase the serotonergic activities of Amitriptyline.Approved
AmlodipineAmlodipine may increase the orthostatic hypotensive activities of Duloxetine.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Duloxetine.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Duloxetine is combined with Amperozide.Experimental
AmphetamineThe metabolism of Amphetamine can be decreased when combined with Duloxetine.Approved, Illicit
Amphotericin BAmphotericin B may increase the orthostatic hypotensive activities of Duloxetine.Approved, Investigational
AmprenavirThe metabolism of Amprenavir can be decreased when combined with Duloxetine.Approved
AmsacrineThe metabolism of Amsacrine can be decreased when combined with Duloxetine.Approved
Amyl NitriteAmyl Nitrite may increase the orthostatic hypotensive activities of Duloxetine.Approved
AnisodamineDuloxetine may increase the tachycardic activities of Anisodamine.Investigational
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Duloxetine.Approved
Aop200704The serum concentration of Aop200704 can be increased when it is combined with Duloxetine.Investigational
ApomorphineApomorphine may increase the orthostatic hypotensive activities of Duloxetine.Approved, Investigational
ApraclonidineApraclonidine may increase the orthostatic hypotensive activities of Duloxetine.Approved
AprindineThe metabolism of Aprindine can be decreased when combined with Duloxetine.Approved
ArbutamineDuloxetine may increase the tachycardic activities of Arbutamine.Approved
ArformoterolDuloxetine may increase the tachycardic activities of Arformoterol.Approved, Investigational
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Duloxetine.Approved, Investigational
ArotinololArotinolol may increase the orthostatic hypotensive activities of Duloxetine.Approved
Arsenic trioxideArsenic trioxide may increase the orthostatic hypotensive activities of Duloxetine.Approved, Investigational
ArtemetherThe metabolism of Artemether can be decreased when combined with Duloxetine.Approved
ArticaineThe risk or severity of adverse effects can be increased when Articaine is combined with Duloxetine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Asenapine.Approved
AstemizoleThe metabolism of Astemizole can be decreased when combined with Duloxetine.Approved, Withdrawn
AtenololAtenolol may increase the orthostatic hypotensive activities of Duloxetine.Approved
AtomoxetineThe metabolism of Duloxetine can be decreased when combined with Atomoxetine.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Duloxetine is combined with Azaperone.Vet Approved
AzelastineThe metabolism of Azelastine can be decreased when combined with Duloxetine.Approved
Azilsartan medoxomilAzilsartan medoxomil may increase the orthostatic hypotensive activities of Duloxetine.Approved
AzithromycinThe metabolism of Duloxetine can be decreased when combined with Azithromycin.Approved
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Duloxetine.Approved
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Duloxetine.Illicit
BarnidipineBarnidipine may increase the orthostatic hypotensive activities of Duloxetine.Approved
BefunololDuloxetine may increase the tachycardic activities of Befunolol.Experimental
BenazeprilBenazepril may increase the orthostatic hypotensive activities of Duloxetine.Approved, Investigational
BendroflumethiazideBendroflumethiazide may increase the orthostatic hypotensive activities of Duloxetine.Approved
BenmoxinBenmoxin may increase the serotonergic activities of Duloxetine.Withdrawn
BenperidolThe risk or severity of adverse effects can be increased when Duloxetine is combined with Benperidol.Investigational
BenzatropineThe metabolism of Benzatropine can be decreased when combined with Duloxetine.Approved
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Duloxetine.Approved
BenzphetamineDuloxetine may decrease the antihypertensive activities of Benzphetamine.Approved, Illicit
Benzyl alcoholThe metabolism of Benzyl alcohol can be decreased when combined with Duloxetine.Approved
BepridilBepridil may increase the orthostatic hypotensive activities of Duloxetine.Approved, Withdrawn
BetaxololBetaxolol may increase the orthostatic hypotensive activities of Duloxetine.Approved
BethanidineDuloxetine may decrease the antihypertensive activities of Bethanidine.Approved
BevantololThe serum concentration of Bevantolol can be increased when it is combined with Duloxetine.Approved
BezitramideBezitramide may increase the serotonergic activities of Duloxetine.Experimental, Illicit, Withdrawn
BifeprunoxThe risk or severity of adverse effects can be increased when Duloxetine is combined with Bifeprunox.Investigational
BisoprololBisoprolol may increase the orthostatic hypotensive activities of Duloxetine.Approved
BitolterolDuloxetine may increase the tachycardic activities of Bitolterol.Withdrawn
BopindololThe serum concentration of Bopindolol can be increased when it is combined with Duloxetine.Approved
BortezomibBortezomib may increase the orthostatic hypotensive activities of Duloxetine.Approved, Investigational
BretyliumBretylium may increase the orthostatic hypotensive activities of Duloxetine.Approved
BrexpiprazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Duloxetine.Approved
BrimonidineBrimonidine may increase the orthostatic hypotensive activities of Duloxetine.Approved
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Duloxetine.Approved, Illicit
BromocriptineBromocriptine may increase the orthostatic hypotensive activities of Duloxetine.Approved, Investigational
BromperidolThe risk or severity of adverse effects can be increased when Duloxetine is combined with Bromperidol.Investigational
BrompheniramineThe metabolism of Brompheniramine can be decreased when combined with Duloxetine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Duloxetine.Approved, Withdrawn
BucindololThe serum concentration of Bucindolol can be increased when it is combined with Duloxetine.Investigational
BufuralolThe metabolism of Bufuralol can be decreased when combined with Duloxetine.Experimental, Investigational
BumetanideBumetanide may increase the orthostatic hypotensive activities of Duloxetine.Approved
BupivacaineBupivacaine may increase the orthostatic hypotensive activities of Duloxetine.Approved, Investigational
BupranololThe serum concentration of Bupranolol can be increased when it is combined with Duloxetine.Approved
BuprenorphineThe metabolism of Buprenorphine can be decreased when combined with Duloxetine.Approved, Illicit, Investigational, Vet Approved
BupropionThe serum concentration of Duloxetine can be increased when it is combined with Bupropion.Approved
BuspironeBuspirone may increase the serotonergic activities of Duloxetine.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Duloxetine.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Butacaine is combined with Duloxetine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Duloxetine.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Butamben is combined with Duloxetine.Approved
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Duloxetine.Approved, Illicit
ButorphanolButorphanol may increase the serotonergic activities of Duloxetine.Approved, Illicit, Vet Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Duloxetine.Approved
CaffeineThe metabolism of Duloxetine can be decreased when combined with Caffeine.Approved
CanagliflozinCanagliflozin may increase the orthostatic hypotensive activities of Duloxetine.Approved
CandesartanCandesartan may increase the orthostatic hypotensive activities of Duloxetine.Approved
CaptoprilCaptopril may increase the orthostatic hypotensive activities of Duloxetine.Approved
CarbamazepineThe metabolism of Carbamazepine can be decreased when combined with Duloxetine.Approved, Investigational
CarbetocinCarbetocin may increase the orthostatic hypotensive activities of Duloxetine.Approved
CarbinoxamineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Duloxetine.Approved
CarfentanilCarfentanil may increase the serotonergic activities of Duloxetine.Illicit, Vet Approved
CariprazineThe metabolism of Cariprazine can be decreased when combined with Duloxetine.Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Duloxetine.Approved
CaroxazoneCaroxazone may increase the serotonergic activities of Duloxetine.Withdrawn
CarteololCarteolol may increase the orthostatic hypotensive activities of Duloxetine.Approved
CarvedilolCarvedilol may increase the orthostatic hypotensive activities of Duloxetine.Approved, Investigational
CelecoxibDuloxetine may increase the antiplatelet activities of Celecoxib.Approved, Investigational
CeliprololThe serum concentration of Celiprolol can be increased when it is combined with Duloxetine.Approved, Investigational
CephalexinThe metabolism of Cephalexin can be decreased when combined with Duloxetine.Approved, Vet Approved
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Duloxetine.Approved
CevimelineThe metabolism of Cevimeline can be decreased when combined with Duloxetine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Duloxetine.Approved, Illicit, Vet Approved
ChlordiazepoxideThe metabolism of Chlordiazepoxide can be decreased when combined with Duloxetine.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Duloxetine.Approved, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Duloxetine.Approved
ChloroquineThe metabolism of Chloroquine can be decreased when combined with Duloxetine.Approved, Vet Approved
ChlorothiazideChlorothiazide may increase the orthostatic hypotensive activities of Duloxetine.Approved, Vet Approved
ChlorphenamineThe metabolism of Chlorphenamine can be decreased when combined with Duloxetine.Approved
ChlorpromazineChlorpromazine may increase the orthostatic hypotensive activities of Duloxetine.Approved, Vet Approved
ChlorpropamideDuloxetine may increase the hypoglycemic activities of Chlorpropamide.Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Duloxetine is combined with Chlorprothixene.Approved, Withdrawn
ChlorthalidoneChlorthalidone may increase the orthostatic hypotensive activities of Duloxetine.Approved
ChlorzoxazoneThe metabolism of Chlorzoxazone can be decreased when combined with Duloxetine.Approved
CholecalciferolThe metabolism of Duloxetine can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CilazaprilCilazapril may increase the orthostatic hypotensive activities of Duloxetine.Approved
CilnidipineCilnidipine may increase the orthostatic hypotensive activities of Duloxetine.Approved
CilostazolThe metabolism of Cilostazol can be decreased when combined with Duloxetine.Approved
CimetidineThe metabolism of Duloxetine can be decreased when combined with Cimetidine.Approved
CinacalcetThe serum concentration of Duloxetine can be increased when it is combined with Cinacalcet.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Duloxetine.Approved, Vet Approved
CinnarizineThe metabolism of Cinnarizine can be decreased when combined with Duloxetine.Approved
CirazolineDuloxetine may increase the tachycardic activities of Cirazoline.Experimental
CitalopramThe risk or severity of adverse effects can be increased when Citalopram is combined with Duloxetine.Approved
ClemastineThe metabolism of Duloxetine can be decreased when combined with Clemastine.Approved
ClenbuterolDuloxetine may increase the tachycardic activities of Clenbuterol.Approved, Vet Approved
ClevidipineClevidipine may increase the orthostatic hypotensive activities of Duloxetine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Clidinium is combined with Duloxetine.Approved
ClobazamThe metabolism of Duloxetine can be decreased when combined with Clobazam.Approved, Illicit
ClofarabineClofarabine may increase the orthostatic hypotensive activities of Duloxetine.Approved, Investigational
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Duloxetine.Investigational
ClomipramineDuloxetine may increase the serotonergic activities of Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Clonazepam is combined with Duloxetine.Approved, Illicit
ClonidineClonidine may increase the orthostatic hypotensive activities of Duloxetine.Approved
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Duloxetine.Approved, Illicit
ClotrimazoleThe metabolism of Duloxetine can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe serum concentration of Clozapine can be increased when it is combined with Duloxetine.Approved
CobicistatThe serum concentration of Duloxetine can be increased when it is combined with Cobicistat.Approved
CocaineThe serum concentration of Duloxetine can be increased when it is combined with Cocaine.Approved, Illicit
CodeineThe therapeutic efficacy of Codeine can be decreased when used in combination with Duloxetine.Approved, Illicit
ConivaptanConivaptan may increase the orthostatic hypotensive activities of Duloxetine.Approved, Investigational
CyamemazineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Cyamemazine.Approved
CyclizineThe risk or severity of adverse effects can be increased when Cyclizine is combined with Duloxetine.Approved
CyclobenzaprineDuloxetine may increase the serotonergic activities of Cyclobenzaprine.Approved
CyclophosphamideThe metabolism of Cyclophosphamide can be decreased when combined with Duloxetine.Approved, Investigational
CyproheptadineThe therapeutic efficacy of Duloxetine can be decreased when used in combination with Cyproheptadine.Approved
Cyproterone acetateThe serum concentration of Duloxetine can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
DantroleneThe risk or severity of adverse effects can be increased when Dantrolene is combined with Duloxetine.Approved
DapagliflozinDapagliflozin may increase the orthostatic hypotensive activities of Duloxetine.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Duloxetine is combined with Dapiprazole.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Duloxetine.Investigational
DarifenacinThe metabolism of Darifenacin can be decreased when combined with Duloxetine.Approved, Investigational
DarunavirThe serum concentration of Duloxetine can be increased when it is combined with Darunavir.Approved
DasabuvirThe metabolism of Dasabuvir can be decreased when combined with Duloxetine.Approved
DebrisoquinThe metabolism of Debrisoquin can be decreased when combined with Duloxetine.Approved
DeferasiroxThe serum concentration of Duloxetine can be increased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe serum concentration of Duloxetine can be increased when it is combined with Delavirdine.Approved
deramciclaneThe risk or severity of adverse effects can be increased when deramciclane is combined with Duloxetine.Investigational
DesfluraneDesflurane may increase the orthostatic hypotensive activities of Duloxetine.Approved
DesipramineDuloxetine may increase the serotonergic activities of Desipramine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Duloxetine.Approved, Investigational
DesmopressinThe risk or severity of adverse effects can be increased when Duloxetine is combined with Desmopressin.Approved
DesvenlafaxineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Desvenlafaxine.Approved
DetomidineDuloxetine may increase the tachycardic activities of Detomidine.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Duloxetine.Approved
DexfenfluramineThe metabolism of Dexfenfluramine can be decreased when combined with Duloxetine.Approved, Illicit, Withdrawn
DexmedetomidineDexmedetomidine may increase the orthostatic hypotensive activities of Duloxetine.Approved, Vet Approved
DexmethylphenidateThe metabolism of Dexmethylphenidate can be decreased when combined with Duloxetine.Approved
DextroamphetamineThe metabolism of Dextroamphetamine can be decreased when combined with Duloxetine.Approved, Illicit
DextromethorphanDuloxetine may increase the serotonergic activities of Dextromethorphan.Approved
DextromoramideDextromoramide may increase the serotonergic activities of Duloxetine.Experimental, Illicit
DextropropoxypheneDextropropoxyphene may increase the serotonergic activities of Duloxetine.Approved, Illicit, Withdrawn
DezocineDezocine may increase the serotonergic activities of Duloxetine.Approved
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Duloxetine.Approved, Illicit, Vet Approved
DiclofenamideDiclofenamide may increase the orthostatic hypotensive activities of Duloxetine.Approved
DicoumarolDuloxetine may increase the anticoagulant activities of Dicoumarol.Approved
DifenoxinThe risk or severity of adverse effects can be increased when Difenoxin is combined with Duloxetine.Approved, Illicit
DihydrocodeineThe metabolism of Dihydrocodeine can be decreased when combined with Duloxetine.Approved, Illicit
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Duloxetine.Approved
DihydroetorphineDihydroetorphine may increase the serotonergic activities of Duloxetine.Experimental, Illicit
DihydromorphineDihydromorphine may increase the serotonergic activities of Duloxetine.Experimental, Illicit
DiltiazemDiltiazem may increase the orthostatic hypotensive activities of Duloxetine.Approved
DimenhydrinateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Duloxetine.Approved
DinutuximabDinutuximab may increase the orthostatic hypotensive activities of Duloxetine.Approved
DiphenhydramineThe metabolism of Diphenhydramine can be decreased when combined with Duloxetine.Approved
DiphenoxylateDiphenoxylate may increase the serotonergic activities of Duloxetine.Approved, Illicit
DipivefrinDuloxetine may increase the tachycardic activities of Dipivefrin.Approved
DipyridamoleDipyridamole may increase the orthostatic hypotensive activities of Duloxetine.Approved
DisopyramideDuloxetine may increase the hypoglycemic activities of Disopyramide.Approved
DobutamineDuloxetine may increase the tachycardic activities of Dobutamine.Approved
DolasetronDolasetron may increase the serotonergic activities of Duloxetine.Approved
DomperidoneThe metabolism of Domperidone can be decreased when combined with Duloxetine.Approved, Investigational, Vet Approved
DonepezilThe metabolism of Donepezil can be decreased when combined with Duloxetine.Approved
DopamineThe metabolism of Dopamine can be decreased when combined with Duloxetine.Approved
DoramectinThe risk or severity of adverse effects can be increased when Doramectin is combined with Duloxetine.Vet Approved
DosulepinThe serum concentration of Dosulepin can be increased when it is combined with Duloxetine.Approved
DoxazosinDoxazosin may increase the orthostatic hypotensive activities of Duloxetine.Approved
DoxepinDuloxetine may increase the serotonergic activities of Doxepin.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Duloxetine.Approved, Investigational
DoxorubicinThe metabolism of Doxorubicin can be decreased when combined with Duloxetine.Approved, Investigational
DoxylamineThe risk or severity of adverse effects can be increased when Doxylamine is combined with Duloxetine.Approved, Vet Approved
DPDPEDPDPE may increase the serotonergic activities of Duloxetine.Investigational
DronedaroneThe metabolism of Dronedarone can be decreased when combined with Duloxetine.Approved
DroperidolThe risk or severity of adverse effects can be increased when Duloxetine is combined with Droperidol.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Duloxetine.Experimental, Illicit
DroxidopaDuloxetine may increase the tachycardic activities of Droxidopa.Approved, Investigational
DulaglutideDuloxetine may increase the hypoglycemic activities of Dulaglutide.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Duloxetine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Duloxetine.Experimental, Illicit
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when ECGONINE METHYL ESTER is combined with Duloxetine.Experimental
EcopipamThe risk or severity of adverse effects can be increased when Duloxetine is combined with Ecopipam.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when Efavirenz is combined with Duloxetine.Approved, Investigational
EfonidipineEfonidipine may increase the orthostatic hypotensive activities of Duloxetine.Approved
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Duloxetine.Approved, Investigational
EliglustatThe serum concentration of Eliglustat can be increased when it is combined with Duloxetine.Approved
EmpagliflozinEmpagliflozin may increase the orthostatic hypotensive activities of Duloxetine.Approved
EnalaprilEnalapril may increase the orthostatic hypotensive activities of Duloxetine.Approved, Vet Approved
EnalaprilatEnalaprilat may increase the orthostatic hypotensive activities of Duloxetine.Approved
EncainideThe metabolism of Encainide can be decreased when combined with Duloxetine.Approved, Withdrawn
EnclomipheneThe metabolism of Enclomiphene can be decreased when combined with Duloxetine.Investigational
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Duloxetine.Approved, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Duloxetine.Approved, Investigational
EphedraDuloxetine may decrease the antihypertensive activities of Ephedra.Approved, Nutraceutical, Withdrawn
EphedrineDuloxetine may increase the tachycardic activities of Ephedrine.Approved
EpinastineThe metabolism of Epinastine can be decreased when combined with Duloxetine.Approved, Investigational
EpinephrineDuloxetine may increase the tachycardic activities of Epinephrine.Approved, Vet Approved
EplerenoneEplerenone may increase the orthostatic hypotensive activities of Duloxetine.Approved
EpoprostenolEpoprostenol may increase the orthostatic hypotensive activities of Duloxetine.Approved
EprosartanEprosartan may increase the orthostatic hypotensive activities of Duloxetine.Approved
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Duloxetine is combined with Ergoloid mesylate.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Ergonovine.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Ergotamine.Approved
ErlotinibThe metabolism of Erlotinib can be decreased when combined with Duloxetine.Approved, Investigational
EscitalopramThe risk or severity of adverse effects can be increased when Duloxetine is combined with Escitalopram.Approved, Investigational
EsmirtazapineDuloxetine may increase the serotonergic activities of Esmirtazapine.Investigational
EsmololEsmolol may increase the orthostatic hypotensive activities of Duloxetine.Approved
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Duloxetine.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Duloxetine.Approved
Etacrynic acidEtacrynic acid may increase the orthostatic hypotensive activities of Duloxetine.Approved
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Duloxetine.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Duloxetine.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Duloxetine.Approved
EthotoinThe risk or severity of adverse effects can be increased when Ethotoin is combined with Duloxetine.Approved
Ethyl biscoumacetateDuloxetine may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Duloxetine.Withdrawn
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Duloxetine.Approved, Illicit
EthylmorphineThe metabolism of Ethylmorphine can be decreased when combined with Duloxetine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Etidocaine is combined with Duloxetine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Duloxetine.Withdrawn
EtilefrineDuloxetine may increase the tachycardic activities of Etilefrine.Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Etizolam is combined with Duloxetine.Approved
EtodolacDuloxetine may increase the antiplatelet activities of Etodolac.Approved, Investigational, Vet Approved
EtomidateDuloxetine may decrease the antihypertensive activities of Etomidate.Approved
EtoperidoneDuloxetine may increase the serotonergic activities of Etoperidone.Approved
EtoricoxibDuloxetine may increase the antiplatelet activities of Etoricoxib.Approved, Investigational
EtorphineEtorphine may increase the serotonergic activities of Duloxetine.Illicit, Vet Approved
ExenatideDuloxetine may increase the hypoglycemic activities of Exenatide.Approved, Investigational
EzogabineThe risk or severity of adverse effects can be increased when Ezogabine is combined with Duloxetine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Felbamate is combined with Duloxetine.Approved
FelodipineFelodipine may increase the orthostatic hypotensive activities of Duloxetine.Approved, Investigational
FencamfamineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Fencamfamine.Approved, Illicit, Withdrawn
FenfluramineDuloxetine may increase the serotonergic activities of Fenfluramine.Illicit, Withdrawn
FenoldopamFenoldopam may increase the orthostatic hypotensive activities of Duloxetine.Approved
FenoterolDuloxetine may increase the tachycardic activities of Fenoterol.Approved
FentanylThe risk or severity of adverse effects can be increased when Duloxetine is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Duloxetine.Approved
FexofenadineThe risk or severity of adverse effects can be increased when Fexofenadine is combined with Duloxetine.Approved
FimasartanFimasartan may increase the orthostatic hypotensive activities of Duloxetine.Approved
FingolimodThe metabolism of Fingolimod can be decreased when combined with Duloxetine.Approved, Investigational
FlecainideThe metabolism of Flecainide can be decreased when combined with Duloxetine.Approved, Withdrawn
FlibanserinThe risk or severity of adverse effects can be increased when Flibanserin is combined with Duloxetine.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Duloxetine.Approved, Illicit
FluindioneDuloxetine may increase the anticoagulant activities of Fluindione.Investigational
FlunarizineThe metabolism of Flunarizine can be decreased when combined with Duloxetine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Duloxetine.Approved, Illicit
FluoxetineThe serum concentration of Duloxetine can be increased when it is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Duloxetine is combined with Flupentixol.Approved, Withdrawn
FluphenazineThe metabolism of Fluphenazine can be decreased when combined with Duloxetine.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Duloxetine.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Duloxetine is combined with Fluspirilene.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Duloxetine.Approved
FluvastatinThe metabolism of Fluvastatin can be decreased when combined with Duloxetine.Approved
FluvoxamineThe serum concentration of Duloxetine can be increased when it is combined with Fluvoxamine.Approved, Investigational
FormoterolDuloxetine may increase the tachycardic activities of Formoterol.Approved, Investigational
FosinoprilFosinopril may increase the orthostatic hypotensive activities of Duloxetine.Approved
FosphenytoinThe risk or severity of adverse effects can be increased when Fosphenytoin is combined with Duloxetine.Approved
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Duloxetine.Approved, Illicit
FrovatriptanThe risk or severity of adverse effects can be increased when Duloxetine is combined with Frovatriptan.Approved, Investigational
FurazolidoneFurazolidone may increase the serotonergic activities of Duloxetine.Approved, Vet Approved
FurosemideFurosemide may increase the orthostatic hypotensive activities of Duloxetine.Approved, Vet Approved
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Duloxetine.Approved, Investigational
gabapentin enacarbilThe risk or severity of adverse effects can be increased when gabapentin enacarbil is combined with Duloxetine.Approved
GalantamineThe metabolism of Galantamine can be decreased when combined with Duloxetine.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Duloxetine.Approved, Illicit
GefitinibThe metabolism of Gefitinib can be decreased when combined with Duloxetine.Approved, Investigational
GepironeThe risk or severity of adverse effects can be increased when Gepirone is combined with Duloxetine.Investigational
GliclazideDuloxetine may increase the hypoglycemic activities of Gliclazide.Approved
GlimepirideDuloxetine may increase the hypoglycemic activities of Glimepiride.Approved
GlipizideDuloxetine may increase the hypoglycemic activities of Glipizide.Approved
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Duloxetine.Approved, Illicit
GlyburideDuloxetine may increase the hypoglycemic activities of Glyburide.Approved
GranisetronGranisetron may increase the serotonergic activities of Duloxetine.Approved, Investigational
GuanabenzDuloxetine may increase the tachycardic activities of Guanabenz.Approved
GuanfacineGuanfacine may increase the orthostatic hypotensive activities of Duloxetine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Duloxetine.Approved, Illicit, Withdrawn
HalofantrineThe metabolism of Halofantrine can be decreased when combined with Duloxetine.Approved
HaloperidolThe metabolism of Haloperidol can be decreased when combined with Duloxetine.Approved
HalothaneHalothane may increase the orthostatic hypotensive activities of Duloxetine.Approved, Vet Approved
HeroinHeroin may increase the serotonergic activities of Duloxetine.Approved, Illicit
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Duloxetine.Approved
HexoprenalineDuloxetine may increase the tachycardic activities of Hexoprenaline.Approved, Withdrawn
HigenamineDuloxetine may increase the tachycardic activities of Higenamine.Investigational
HydracarbazineHydracarbazine may increase the serotonergic activities of Duloxetine.Approved
HydralazineHydralazine may increase the orthostatic hypotensive activities of Duloxetine.Approved
HydrochlorothiazideHydrochlorothiazide may increase the orthostatic hypotensive activities of Duloxetine.Approved, Vet Approved
HydrocodoneThe metabolism of Hydrocodone can be decreased when combined with Duloxetine.Approved, Illicit
HydroflumethiazideHydroflumethiazide may increase the orthostatic hypotensive activities of Duloxetine.Approved
HydromorphoneThe metabolism of Hydromorphone can be decreased when combined with Duloxetine.Approved, Illicit
HydroxyzineThe risk or severity of adverse effects can be increased when Hydroxyzine is combined with Duloxetine.Approved
IbrutinibThe metabolism of Ibrutinib can be decreased when combined with Duloxetine.Approved
IdarubicinThe metabolism of Idarubicin can be decreased when combined with Duloxetine.Approved
IloperidoneThe metabolism of Iloperidone can be decreased when combined with Duloxetine.Approved
IloprostIloprost may increase the orthostatic hypotensive activities of Duloxetine.Approved, Investigational
ImatinibThe metabolism of Imatinib can be decreased when combined with Duloxetine.Approved
ImidaprilImidapril may increase the orthostatic hypotensive activities of Duloxetine.Investigational
ImipramineDuloxetine may increase the serotonergic activities of Imipramine.Approved
IndalpineDuloxetine may increase the serotonergic activities of Indalpine.Investigational, Withdrawn
IndapamideIndapamide may increase the orthostatic hypotensive activities of Duloxetine.Approved
IndenololThe serum concentration of Indenolol can be increased when it is combined with Duloxetine.Withdrawn
IndinavirThe metabolism of Duloxetine can be decreased when combined with Indinavir.Approved
IndoraminIndoramin may increase the orthostatic hypotensive activities of Duloxetine.Withdrawn
Insulin AspartDuloxetine may increase the hypoglycemic activities of Insulin Aspart.Approved
Insulin DetemirDuloxetine may increase the hypoglycemic activities of Insulin Detemir.Approved
Insulin GlargineDuloxetine may increase the hypoglycemic activities of Insulin Glargine.Approved
Insulin GlulisineDuloxetine may increase the hypoglycemic activities of Insulin Glulisine.Approved
Insulin HumanDuloxetine may increase the hypoglycemic activities of Insulin Human.Approved, Investigational
Insulin LisproDuloxetine may increase the hypoglycemic activities of Insulin Lispro.Approved
IobenguaneThe therapeutic efficacy of Iobenguane can be decreased when used in combination with Duloxetine.Approved
Ioflupane I-123Duloxetine may decrease effectiveness of Ioflupane I-123 as a diagnostic agent.Approved
Ipratropium bromideThe metabolism of Ipratropium bromide can be decreased when combined with Duloxetine.Approved
IproclozideIproclozide may increase the serotonergic activities of Duloxetine.Withdrawn
IproniazidIproniazid may increase the serotonergic activities of Duloxetine.Withdrawn
IrbesartanIrbesartan may increase the orthostatic hypotensive activities of Duloxetine.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the orthostatic hypotensive activities of Duloxetine.Approved
IsoetarineDuloxetine may increase the tachycardic activities of Isoetarine.Approved
IsofluraneIsoflurane may increase the orthostatic hypotensive activities of Duloxetine.Approved, Vet Approved
IsoniazidThe metabolism of Duloxetine can be decreased when combined with Isoniazid.Approved
IsoprenalineDuloxetine may increase the tachycardic activities of Isoprenaline.Approved
Isosorbide DinitrateIsosorbide Dinitrate may increase the orthostatic hypotensive activities of Duloxetine.Approved
Isosorbide MononitrateIsosorbide Mononitrate may increase the orthostatic hypotensive activities of Duloxetine.Approved
IsoxsuprineIsoxsuprine may increase the orthostatic hypotensive activities of Duloxetine.Approved, Withdrawn
IsradipineIsradipine may increase the orthostatic hypotensive activities of Duloxetine.Approved
IxazomibThe metabolism of Ixazomib can be decreased when combined with Duloxetine.Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Duloxetine.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Duloxetine.Approved
KetobemidoneKetobemidone may increase the serotonergic activities of Duloxetine.Approved
KetoconazoleThe metabolism of Duloxetine can be decreased when combined with Ketoconazole.Approved, Investigational
L-TryptophanL-Tryptophan may increase the serotonergic activities of Duloxetine.Approved, Nutraceutical
LabetalolLabetalol may increase the orthostatic hypotensive activities of Duloxetine.Approved
LacidipineLacidipine may increase the orthostatic hypotensive activities of Duloxetine.Approved
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Duloxetine.Approved, Investigational
LanreotideDuloxetine may increase the hypoglycemic activities of Lanreotide.Approved
LercanidipineLercanidipine may increase the orthostatic hypotensive activities of Duloxetine.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Duloxetine.Approved, Investigational
LevobunololLevobunolol may increase the orthostatic hypotensive activities of Duloxetine.Approved
LevobupivacaineLevobupivacaine may increase the orthostatic hypotensive activities of Duloxetine.Approved
LevocabastineThe risk or severity of adverse effects can be increased when Levocabastine is combined with Duloxetine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Duloxetine.Approved
LevodopaLevodopa may increase the orthostatic hypotensive activities of Duloxetine.Approved
Levomethadyl AcetateLevomethadyl Acetate may increase the serotonergic activities of Duloxetine.Approved
LevomilnacipranThe risk or severity of adverse effects can be increased when Duloxetine is combined with Levomilnacipran.Approved
LevorphanolLevorphanol may increase the serotonergic activities of Duloxetine.Approved
LevosimendanLevosimendan may increase the orthostatic hypotensive activities of Duloxetine.Approved, Investigational
LevothyroxineThe therapeutic efficacy of Levothyroxine can be decreased when used in combination with Duloxetine.Approved
LidocaineThe metabolism of Duloxetine can be decreased when combined with Lidocaine.Approved, Vet Approved
LinezolidLinezolid may increase the serotonergic activities of Duloxetine.Approved, Investigational
LiothyronineThe therapeutic efficacy of Liothyronine can be decreased when used in combination with Duloxetine.Approved, Vet Approved
LiotrixThe therapeutic efficacy of Liotrix can be decreased when used in combination with Duloxetine.Approved
LiraglutideDuloxetine may increase the hypoglycemic activities of Liraglutide.Approved
LisinoprilLisinopril may increase the orthostatic hypotensive activities of Duloxetine.Approved, Investigational
LisurideThe metabolism of Lisuride can be decreased when combined with Duloxetine.Approved
LithiumLithium may increase the serotonergic activities of Duloxetine.Approved
LofentanilLofentanil may increase the serotonergic activities of Duloxetine.Illicit
LofexidineLofexidine may increase the orthostatic hypotensive activities of Duloxetine.Approved, Investigational
LomustineThe metabolism of Lomustine can be decreased when combined with Duloxetine.Approved
LoperamideThe metabolism of Loperamide can be decreased when combined with Duloxetine.Approved
LopinavirThe serum concentration of Duloxetine can be increased when it is combined with Lopinavir.Approved
LoratadineThe metabolism of Loratadine can be decreased when combined with Duloxetine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Duloxetine.Approved
LorcaserinThe risk or severity of adverse effects can be increased when Duloxetine is combined with Lorcaserin.Approved
LosartanLosartan may increase the orthostatic hypotensive activities of Duloxetine.Approved
LoxapineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Loxapine.Approved
Lu AA21004Duloxetine may increase the serotonergic activities of Lu AA21004.Investigational
LumefantrineThe metabolism of Duloxetine can be decreased when combined with Lumefantrine.Approved
LumiracoxibDuloxetine may increase the antiplatelet activities of Lumiracoxib.Approved, Investigational
LurasidoneThe risk or severity of adverse effects can be increased when Duloxetine is combined with Lurasidone.Approved
Magnesium SulfateThe risk or severity of adverse effects can be increased when Magnesium Sulfate is combined with Duloxetine.Approved, Vet Approved
MannitolMannitol may increase the orthostatic hypotensive activities of Duloxetine.Approved, Investigational
MaprotilineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Maprotiline.Approved
MebanazineMebanazine may increase the serotonergic activities of Duloxetine.Withdrawn
MecamylamineMecamylamine may increase the orthostatic hypotensive activities of Duloxetine.Approved
MecaserminDuloxetine may increase the hypoglycemic activities of Mecasermin.Approved, Investigational
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Duloxetine.Approved
MedetomidineDuloxetine may increase the tachycardic activities of Medetomidine.Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Duloxetine.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Duloxetine is combined with Melperone.Approved
MephentermineDuloxetine may increase the tachycardic activities of Mephentermine.Approved
MephenytoinThe metabolism of Mephenytoin can be decreased when combined with Duloxetine.Investigational, Withdrawn
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Duloxetine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Duloxetine.Approved, Illicit
MequitazineThe metabolism of Mequitazine can be decreased when combined with Duloxetine.Approved
MesoridazineThe metabolism of Mesoridazine can be decreased when combined with Duloxetine.Approved
MetaraminolDuloxetine may increase the tachycardic activities of Metaraminol.Approved, Investigational
MetaxaloneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Duloxetine.Approved
MetforminDuloxetine may increase the hypoglycemic activities of Metformin.Approved
MethadoneThe metabolism of Methadone can be decreased when combined with Duloxetine.Approved
Methadyl AcetateMethadyl Acetate may increase the serotonergic activities of Duloxetine.Approved, Illicit
MethamphetamineThe metabolism of Methamphetamine can be decreased when combined with Duloxetine.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Duloxetine.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Duloxetine.Illicit, Withdrawn
MethazolamideMethazolamide may increase the orthostatic hypotensive activities of Duloxetine.Approved
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Duloxetine.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Duloxetine.Approved
MethotrimeprazineThe serum concentration of Duloxetine can be increased when it is combined with Methotrimeprazine.Approved
MethoxamineDuloxetine may increase the tachycardic activities of Methoxamine.Approved
MethoxyfluraneThe metabolism of Methoxyflurane can be decreased when combined with Duloxetine.Approved, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Methsuximide is combined with Duloxetine.Approved
MethyclothiazideMethyclothiazide may increase the orthostatic hypotensive activities of Duloxetine.Approved
MethyldopaMethyldopa may increase the orthostatic hypotensive activities of Duloxetine.Approved
Methylene blueDuloxetine may increase the serotonergic activities of Methylene blue.Investigational
MethylphenidateThe metabolism of Methylphenidate can be decreased when combined with Duloxetine.Approved, Investigational
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Duloxetine.Approved
MethyprylonThe metabolism of Methyprylon can be decreased when combined with Duloxetine.Approved, Illicit, Withdrawn
MetipranololMetipranolol may increase the orthostatic hypotensive activities of Duloxetine.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Duloxetine.Approved, Investigational
MetolazoneMetolazone may increase the orthostatic hypotensive activities of Duloxetine.Approved
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Duloxetine.Approved, Investigational
MetyrosineThe risk or severity of adverse effects can be increased when Metyrosine is combined with Duloxetine.Approved
MexiletineThe serum concentration of Duloxetine can be increased when it is combined with Mexiletine.Approved
MianserinThe metabolism of Mianserin can be decreased when combined with Duloxetine.Approved
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Duloxetine.Approved, Illicit
MidodrineDuloxetine may increase the tachycardic activities of Midodrine.Approved
MifepristoneDuloxetine may increase the hypoglycemic activities of Mifepristone.Approved, Investigational
MiglitolDuloxetine may increase the hypoglycemic activities of Miglitol.Approved
MilnacipranThe risk or severity of adverse effects can be increased when Duloxetine is combined with Milnacipran.Approved
MinaprineMinaprine may increase the serotonergic activities of Duloxetine.Approved
MinoxidilMinoxidil may increase the orthostatic hypotensive activities of Duloxetine.Approved
MirabegronDuloxetine may increase the tachycardic activities of Mirabegron.Approved
MirtazapineDuloxetine may increase the serotonergic activities of Mirtazapine.Approved
MoclobemideMoclobemide may increase the serotonergic activities of Duloxetine.Approved
MoexiprilMoexipril may increase the orthostatic hypotensive activities of Duloxetine.Approved
MolindoneThe risk or severity of adverse effects can be increased when Duloxetine is combined with Molindone.Approved
MorphineMorphine may increase the orthostatic hypotensive activities of Duloxetine.Approved, Investigational
MoxonidineMoxonidine may increase the orthostatic hypotensive activities of Duloxetine.Approved
NabiloneNabilone may increase the orthostatic hypotensive activities of Duloxetine.Approved, Investigational
NabumetoneDuloxetine may increase the antiplatelet activities of Nabumetone.Approved
NadololNadolol may increase the orthostatic hypotensive activities of Duloxetine.Approved
NalbuphineNalbuphine may increase the serotonergic activities of Duloxetine.Approved
NaphazolineDuloxetine may increase the tachycardic activities of Naphazoline.Approved
NaratriptanThe risk or severity of adverse effects can be increased when Duloxetine is combined with Naratriptan.Approved, Investigational
NateglinideThe metabolism of Nateglinide can be decreased when combined with Duloxetine.Approved, Investigational
NebivololThe serum concentration of Nebivolol can be increased when it is combined with Duloxetine.Approved, Investigational
NefazodoneThe risk or severity of adverse effects can be increased when Duloxetine is combined with Nefazodone.Approved, Withdrawn
NesiritideNesiritide may increase the orthostatic hypotensive activities of Duloxetine.Approved, Investigational
NetupitantThe metabolism of Netupitant can be decreased when combined with Duloxetine.Approved
NevirapineThe metabolism of Duloxetine can be decreased when combined with Nevirapine.Approved
NialamideNialamide may increase the serotonergic activities of Duloxetine.Withdrawn
NicardipineNicardipine may increase the orthostatic hypotensive activities of Duloxetine.Approved
NicergolineThe metabolism of Nicergoline can be decreased when combined with Duloxetine.Approved
NicotineThe metabolism of Nicotine can be decreased when combined with Duloxetine.Approved
NifedipineNifedipine may increase the orthostatic hypotensive activities of Duloxetine.Approved
NilotinibThe metabolism of Duloxetine can be decreased when combined with Nilotinib.Approved, Investigational
NilvadipineNilvadipine may increase the orthostatic hypotensive activities of Duloxetine.Approved
NimodipineNimodipine may increase the orthostatic hypotensive activities of Duloxetine.Approved
NisoldipineNisoldipine may increase the orthostatic hypotensive activities of Duloxetine.Approved
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Duloxetine.Approved
NitrendipineNitrendipine may increase the orthostatic hypotensive activities of Duloxetine.Approved
Nitric OxideNitric Oxide may increase the orthostatic hypotensive activities of Duloxetine.Approved
NitrofuralThe metabolism of Nitrofural can be decreased when combined with Duloxetine.Approved, Vet Approved
NitroglycerinNitroglycerin may increase the orthostatic hypotensive activities of Duloxetine.Approved, Investigational
NitroprussideNitroprusside may increase the orthostatic hypotensive activities of Duloxetine.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Duloxetine.Approved, Vet Approved
NorepinephrineDuloxetine may increase the tachycardic activities of Norepinephrine.Approved
NormethadoneNormethadone may increase the serotonergic activities of Duloxetine.Approved, Illicit
NortriptylineDuloxetine may increase the serotonergic activities of Nortriptyline.Approved
NylidrinDuloxetine may increase the tachycardic activities of Nylidrin.Approved
ObinutuzumabObinutuzumab may increase the orthostatic hypotensive activities of Duloxetine.Approved
OctamoxinOctamoxin may increase the serotonergic activities of Duloxetine.Withdrawn
OctreotideDuloxetine may increase the hypoglycemic activities of Octreotide.Approved, Investigational
OlanzapineDuloxetine may increase the serotonergic activities of Olanzapine.Approved, Investigational
OlmesartanOlmesartan may increase the orthostatic hypotensive activities of Duloxetine.Approved, Investigational
OlodaterolDuloxetine may increase the tachycardic activities of Olodaterol.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Duloxetine.Approved
OndansetronOndansetron may increase the serotonergic activities of Duloxetine.Approved
OpipramolDuloxetine may increase the serotonergic activities of Opipramol.Investigational
OpiumOpium may increase the serotonergic activities of Duloxetine.Approved, Illicit
OrciprenalineDuloxetine may increase the tachycardic activities of Orciprenaline.Approved
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Duloxetine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Duloxetine is combined with Osanetant.Investigational
OsimertinibThe serum concentration of Duloxetine can be decreased when it is combined with Osimertinib.Approved
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Duloxetine.Approved
OxetacaineThe risk or severity of adverse effects can be increased when Oxetacaine is combined with Duloxetine.Investigational
OxprenololOxprenolol may increase the orthostatic hypotensive activities of Duloxetine.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Duloxetine.Approved
OxycodoneThe metabolism of Oxycodone can be decreased when combined with Duloxetine.Approved, Illicit, Investigational
OxymetazolineDuloxetine may increase the tachycardic activities of Oxymetazoline.Approved
OxymorphoneThe metabolism of Oxymorphone can be decreased when combined with Duloxetine.Approved, Investigational, Vet Approved
PaclitaxelPaclitaxel may increase the orthostatic hypotensive activities of Duloxetine.Approved, Vet Approved
PaliperidoneDuloxetine may decrease the antihypertensive activities of Paliperidone.Approved
PalonosetronPalonosetron may increase the serotonergic activities of Duloxetine.Approved, Investigational
PanobinostatThe serum concentration of Duloxetine can be increased when it is combined with Panobinostat.Approved, Investigational
PapaverinePapaverine may increase the orthostatic hypotensive activities of Duloxetine.Approved
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Duloxetine.Approved
ParecoxibDuloxetine may increase the antiplatelet activities of Parecoxib.Approved
PargylinePargyline may increase the serotonergic activities of Duloxetine.Approved
ParoxetineDuloxetine may increase the serotonergic activities of Paroxetine.Approved, Investigational
PasireotideDuloxetine may increase the hypoglycemic activities of Pasireotide.Approved
PazopanibThe metabolism of Pazopanib can be decreased when combined with Duloxetine.Approved
Peginterferon alfa-2bThe serum concentration of Duloxetine can be decreased when it is combined with Peginterferon alfa-2b.Approved
PenbutololPenbutolol may increase the orthostatic hypotensive activities of Duloxetine.Approved, Investigational
PentamidineThe metabolism of Pentamidine can be decreased when combined with Duloxetine.Approved
PentazocinePentazocine may increase the serotonergic activities of Duloxetine.Approved, Vet Approved
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Duloxetine.Approved, Vet Approved
PerampanelThe risk or severity of adverse effects can be increased when Perampanel is combined with Duloxetine.Approved
PerazineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Perazine.Investigational
PergolideDuloxetine may decrease the antihypertensive activities of Pergolide.Approved, Vet Approved, Withdrawn
PerhexilineThe metabolism of Perhexiline can be decreased when combined with Duloxetine.Approved
PerindoprilPerindopril may increase the orthostatic hypotensive activities of Duloxetine.Approved
PerospironeThe risk or severity of adverse effects can be increased when Duloxetine is combined with Perospirone.Approved
PerphenazineThe metabolism of Perphenazine can be decreased when combined with Duloxetine.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Duloxetine.Approved
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Duloxetine.Withdrawn
PhenelzinePhenelzine may increase the orthostatic hypotensive activities of Duloxetine.Approved
PhenforminThe metabolism of Phenformin can be decreased when combined with Duloxetine.Approved, Withdrawn
PhenindioneDuloxetine may increase the anticoagulant activities of Phenindione.Approved
PheniprazinePheniprazine may increase the serotonergic activities of Duloxetine.Withdrawn
PhenobarbitalThe metabolism of Duloxetine can be increased when combined with Phenobarbital.Approved
PhenoxybenzaminePhenoxybenzamine may increase the orthostatic hypotensive activities of Duloxetine.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Phenoxyethanol is combined with Duloxetine.Approved
PhenoxypropazinePhenoxypropazine may increase the serotonergic activities of Duloxetine.Withdrawn
PhenprocoumonDuloxetine may increase the anticoagulant activities of Phenprocoumon.Approved
PhentolaminePhentolamine may increase the orthostatic hypotensive activities of Duloxetine.Approved
PhenylephrineDuloxetine may increase the tachycardic activities of Phenylephrine.Approved
PhenylpropanolamineDuloxetine may increase the tachycardic activities of Phenylpropanolamine.Approved, Vet Approved, Withdrawn
PhenytoinThe risk or severity of adverse effects can be increased when Phenytoin is combined with Duloxetine.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Duloxetine is combined with Pimozide.Approved
PindololPindolol may increase the orthostatic hypotensive activities of Duloxetine.Approved
PioglitazoneDuloxetine may increase the hypoglycemic activities of Pioglitazone.Approved, Investigational
PipamperonePipamperone may increase the orthostatic hypotensive activities of Duloxetine.Approved
PiperazineThe metabolism of Piperazine can be decreased when combined with Duloxetine.Approved, Vet Approved
PipotiazineThe metabolism of Pipotiazine can be decreased when combined with Duloxetine.Approved
PirbuterolDuloxetine may increase the tachycardic activities of Pirbuterol.Approved
PiritramidePiritramide may increase the serotonergic activities of Duloxetine.Investigational
PirlindolePirlindole may increase the serotonergic activities of Duloxetine.Approved
PivhydrazinePivhydrazine may increase the serotonergic activities of Duloxetine.Withdrawn
PizotifenThe risk or severity of adverse effects can be increased when Pizotifen is combined with Duloxetine.Approved
PolythiazideDuloxetine may increase the hyponatremic activities of Polythiazide.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Duloxetine.Approved
PonatinibThe metabolism of Ponatinib can be decreased when combined with Duloxetine.Approved
PractololThe serum concentration of Practolol can be increased when it is combined with Duloxetine.Approved
PramipexolePramipexole may increase the orthostatic hypotensive activities of Duloxetine.Approved, Investigational
PramlintideDuloxetine may increase the hypoglycemic activities of Pramlintide.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Duloxetine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Duloxetine.Approved, Illicit
PrazosinPrazosin may increase the orthostatic hypotensive activities of Duloxetine.Approved
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Duloxetine.Approved, Illicit, Investigational
PregnanoloneThe risk or severity of adverse effects can be increased when Pregnanolone is combined with Duloxetine.Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Duloxetine.Approved
PrimidoneThe metabolism of Duloxetine can be increased when combined with Primidone.Approved, Vet Approved
ProcainamideThe metabolism of Procainamide can be decreased when combined with Duloxetine.Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Duloxetine.Approved, Investigational, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Procarbazine.Approved
ProcaterolDuloxetine may increase the tachycardic activities of Procaterol.Approved
ProchlorperazineThe metabolism of Prochlorperazine can be decreased when combined with Duloxetine.Approved, Vet Approved
ProgesteroneThe metabolism of Progesterone can be decreased when combined with Duloxetine.Approved, Vet Approved
PromazineThe metabolism of Duloxetine can be decreased when combined with Promazine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Promethazine.Approved
PropafenoneThe serum concentration of Duloxetine can be increased when it is combined with Propafenone.Approved
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Duloxetine.Approved, Vet Approved
PropericiazineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Propericiazine.Approved
PropofolPropofol may increase the orthostatic hypotensive activities of Duloxetine.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Propoxycaine is combined with Duloxetine.Approved
PropranololPropranolol may increase the orthostatic hypotensive activities of Duloxetine.Approved, Investigational
ProthipendylThe risk or severity of adverse effects can be increased when Duloxetine is combined with Prothipendyl.Investigational
ProtriptylineDuloxetine may increase the serotonergic activities of Protriptyline.Approved
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with Duloxetine.Investigational
PseudoephedrineDuloxetine may increase the tachycardic activities of Pseudoephedrine.Approved
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Duloxetine.Approved, Illicit
QuetiapineQuetiapine may increase the orthostatic hypotensive activities of Duloxetine.Approved
QuinaprilQuinapril may increase the orthostatic hypotensive activities of Duloxetine.Approved, Investigational
QuinethazoneDuloxetine may increase the hyponatremic activities of Quinethazone.Approved
QuinidineThe serum concentration of Duloxetine can be increased when it is combined with Quinidine.Approved
QuinineThe metabolism of Duloxetine can be decreased when combined with Quinine.Approved
RacepinephrineDuloxetine may increase the tachycardic activities of Racepinephrine.Approved
RacloprideThe risk or severity of adverse effects can be increased when Duloxetine is combined with Raclopride.Investigational
RactopamineDuloxetine may increase the tachycardic activities of Ractopamine.Vet Approved
RamelteonThe risk or severity of adverse effects can be increased when Ramelteon is combined with Duloxetine.Approved, Investigational
RamiprilRamipril may increase the orthostatic hypotensive activities of Duloxetine.Approved
RanitidineThe metabolism of Ranitidine can be decreased when combined with Duloxetine.Approved
RanolazineThe metabolism of Duloxetine can be decreased when combined with Ranolazine.Approved, Investigational
RasagilineRasagiline may increase the orthostatic hypotensive activities of Duloxetine.Approved
RemifentanilRemifentanil may increase the orthostatic hypotensive activities of Duloxetine.Approved
RemoxiprideThe metabolism of Remoxipride can be decreased when combined with Duloxetine.Approved, Withdrawn
RepaglinideDuloxetine may increase the hypoglycemic activities of Repaglinide.Approved, Investigational
repinotanThe metabolism of repinotan can be decreased when combined with Duloxetine.Investigational
ReserpineReserpine may increase the orthostatic hypotensive activities of Duloxetine.Approved
RifampicinThe metabolism of Duloxetine can be increased when combined with Rifampicin.Approved
RilmenidineDuloxetine may increase the tachycardic activities of Rilmenidine.Investigational
RiociguatRiociguat may increase the orthostatic hypotensive activities of Duloxetine.Approved
RisperidoneThe metabolism of Risperidone can be decreased when combined with Duloxetine.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Duloxetine is combined with Ritanserin.Investigational
RitobegronDuloxetine may increase the tachycardic activities of Ritobegron.Investigational
RitodrineDuloxetine may increase the tachycardic activities of Ritodrine.Approved
RitonavirThe serum concentration of Duloxetine can be increased when it is combined with Ritonavir.Approved, Investigational
RizatriptanThe risk or severity of adverse effects can be increased when Duloxetine is combined with Rizatriptan.Approved
RofecoxibDuloxetine may increase the antiplatelet activities of Rofecoxib.Investigational, Withdrawn
RolapitantThe metabolism of Duloxetine can be decreased when combined with Rolapitant.Approved
RomifidineDuloxetine may increase the tachycardic activities of Romifidine.Vet Approved
RopiniroleRopinirole may increase the orthostatic hypotensive activities of Duloxetine.Approved, Investigational
RopivacaineRopivacaine may increase the orthostatic hypotensive activities of Duloxetine.Approved
RosiglitazoneDuloxetine may increase the hypoglycemic activities of Rosiglitazone.Approved, Investigational
RotigotineRotigotine may increase the orthostatic hypotensive activities of Duloxetine.Approved
S-EthylisothioureaThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Duloxetine.Experimental
SacubitrilSacubitril may increase the orthostatic hypotensive activities of Duloxetine.Approved
SafrazineSafrazine may increase the serotonergic activities of Duloxetine.Withdrawn
Sage 547The risk or severity of adverse effects can be increased when Sage 547 is combined with Duloxetine.Investigational
SalbutamolDuloxetine may increase the tachycardic activities of Salbutamol.Approved, Vet Approved
SalmeterolDuloxetine may increase the tachycardic activities of Salmeterol.Approved
SaquinavirThe metabolism of Saquinavir can be decreased when combined with Duloxetine.Approved, Investigational
SaxagliptinDuloxetine may increase the hypoglycemic activities of Saxagliptin.Approved
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Duloxetine.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Duloxetine.Approved, Vet Approved
SelegilineSelegiline may increase the orthostatic hypotensive activities of Duloxetine.Approved, Investigational, Vet Approved
SertindoleThe metabolism of Sertindole can be decreased when combined with Duloxetine.Approved, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Sertraline.Approved
SevofluraneSevoflurane may increase the orthostatic hypotensive activities of Duloxetine.Approved, Vet Approved
SildenafilThe metabolism of Sildenafil can be decreased when combined with Duloxetine.Approved, Investigational
SimeprevirThe metabolism of Duloxetine can be decreased when combined with Simeprevir.Approved
SimvastatinThe metabolism of Simvastatin can be decreased when combined with Duloxetine.Approved
SitagliptinDuloxetine may increase the hypoglycemic activities of Sitagliptin.Approved, Investigational
Sodium NitriteSodium Nitrite may increase the orthostatic hypotensive activities of Duloxetine.Approved
Sodium oxybateThe risk or severity of adverse effects can be increased when Sodium oxybate is combined with Duloxetine.Approved
SolabegronDuloxetine may increase the tachycardic activities of Solabegron.Investigational
SotalolSotalol may increase the orthostatic hypotensive activities of Duloxetine.Approved
SparteineThe metabolism of Sparteine can be decreased when combined with Duloxetine.Experimental
SpironolactoneSpironolactone may increase the orthostatic hypotensive activities of Duloxetine.Approved
SR 58611Duloxetine may increase the tachycardic activities of SR 58611.Investigational
StiripentolThe serum concentration of Duloxetine can be increased when it is combined with Stiripentol.Approved
StreptokinaseStreptokinase may increase the orthostatic hypotensive activities of Duloxetine.Approved
SufentanilSufentanil may increase the orthostatic hypotensive activities of Duloxetine.Approved, Investigational
SulfadiazineDuloxetine may increase the hypoglycemic activities of Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleDuloxetine may increase the hypoglycemic activities of Sulfamethoxazole.Approved
SulfisoxazoleDuloxetine may increase the hypoglycemic activities of Sulfisoxazole.Approved, Vet Approved
SulpirideThe risk or severity of adverse effects can be increased when Duloxetine is combined with Sulpiride.Approved
SumatriptanThe risk or severity of adverse effects can be increased when Duloxetine is combined with Sumatriptan.Approved, Investigational
SunitinibDuloxetine may increase the hypoglycemic activities of Sunitinib.Approved, Investigational
SuvorexantThe risk or severity of adverse effects can be increased when Suvorexant is combined with Duloxetine.Approved
SynephrineDuloxetine may increase the tachycardic activities of Synephrine.Experimental
TamoxifenThe serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Duloxetine resulting in a loss in efficacy.Approved
TamsulosinTamsulosin may increase the orthostatic hypotensive activities of Duloxetine.Approved, Investigational
TandospironeThe risk or severity of adverse effects can be increased when Tandospirone is combined with Duloxetine.Investigational
TapentadolThe risk or severity of adverse effects can be increased when Duloxetine is combined with Tapentadol.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Tasimelteon is combined with Duloxetine.Approved
Tedizolid PhosphateTedizolid Phosphate may increase the serotonergic activities of Duloxetine.Approved
TegaserodThe metabolism of Tegaserod can be decreased when combined with Duloxetine.Investigational, Withdrawn
TelmisartanTelmisartan may increase the orthostatic hypotensive activities of Duloxetine.Approved, Investigational
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Duloxetine.Approved
TenofovirThe metabolism of Duloxetine can be decreased when combined with Tenofovir.Approved, Investigational
TerazosinTerazosin may increase the orthostatic hypotensive activities of Duloxetine.Approved
TerbinafineThe serum concentration of Duloxetine can be increased when it is combined with Terbinafine.Approved, Investigational, Vet Approved
TerbutalineDuloxetine may increase the tachycardic activities of Terbutaline.Approved
TerfenadineThe metabolism of Terfenadine can be decreased when combined with Duloxetine.Withdrawn
TeriflunomideThe serum concentration of Duloxetine can be decreased when it is combined with Teriflunomide.Approved
TesmilifeneThe metabolism of Tesmilifene can be decreased when combined with Duloxetine.Investigational
TetrabenazineThe metabolism of Tetrabenazine can be decreased when combined with Duloxetine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Duloxetine.Approved, Vet Approved
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Duloxetine.Investigational
ThalidomideThalidomide may increase the orthostatic hypotensive activities of Duloxetine.Approved, Investigational, Withdrawn
TheophyllineThe metabolism of Duloxetine can be decreased when combined with Theophylline.Approved
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Duloxetine.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Duloxetine.Approved, Vet Approved
ThioproperazineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Thioproperazine.Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Duloxetine.Approved
ThiothixeneThe risk or severity of adverse effects can be increased when Duloxetine is combined with Thiothixene.Approved
Thyroid, porcineThe therapeutic efficacy of Thyroid, porcine can be decreased when used in combination with Duloxetine.Approved
TiagabineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Duloxetine.Approved
TianeptineDuloxetine may increase the serotonergic activities of Tianeptine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Duloxetine is combined with Tiapride.Investigational
TiclopidineThe metabolism of Duloxetine can be decreased when combined with Ticlopidine.Approved
TiletamineThe risk or severity of adverse effects can be increased when Tiletamine is combined with Duloxetine.Vet Approved
TimololTimolol may increase the orthostatic hypotensive activities of Duloxetine.Approved
TiotropiumThe metabolism of Tiotropium can be decreased when combined with Duloxetine.Approved
TipranavirThe serum concentration of Duloxetine can be increased when it is combined with Tipranavir.Approved, Investigational
TizanidineTizanidine may increase the orthostatic hypotensive activities of Duloxetine.Approved
TolazamideDuloxetine may increase the hypoglycemic activities of Tolazamide.Approved
TolazolineTolazoline may increase the orthostatic hypotensive activities of Duloxetine.Approved, Vet Approved
TolbutamideDuloxetine may increase the hypoglycemic activities of Tolbutamide.Approved
TolcaponeTolcapone may increase the orthostatic hypotensive activities of Duloxetine.Approved, Withdrawn
ToloxatoneToloxatone may increase the serotonergic activities of Duloxetine.Approved
TolterodineThe metabolism of Tolterodine can be decreased when combined with Duloxetine.Approved, Investigational
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Duloxetine.Approved
TorasemideTorasemide may increase the orthostatic hypotensive activities of Duloxetine.Approved
TrabectedinThe metabolism of Trabectedin can be decreased when combined with Duloxetine.Approved, Investigational
TramadolDuloxetine may increase the neuroexcitatory activities of Tramadol.Approved, Investigational
TrandolaprilTrandolapril may increase the orthostatic hypotensive activities of Duloxetine.Approved
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the serotonergic activities of Duloxetine.Experimental
TranylcypromineTranylcypromine may increase the orthostatic hypotensive activities of Duloxetine.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Duloxetine is combined with Trazodone.Approved, Investigational
TretinoinTretinoin may increase the orthostatic hypotensive activities of Duloxetine.Approved, Investigational, Nutraceutical
TriamtereneTriamterene may increase the orthostatic hypotensive activities of Duloxetine.Approved
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Duloxetine.Approved
TrichlormethiazideDuloxetine may increase the hyponatremic activities of Trichlormethiazide.Approved, Vet Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Trifluoperazine.Approved
TriflupromazineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Triflupromazine.Approved, Vet Approved
TrimipramineDuloxetine may increase the serotonergic activities of Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Duloxetine.Approved
TropisetronTropisetron may increase the serotonergic activities of Duloxetine.Investigational
TulobuterolDuloxetine may increase the tachycardic activities of Tulobuterol.Investigational
Uc1010The risk or severity of adverse effects can be increased when Uc1010 is combined with Duloxetine.Investigational
UmeclidiniumThe metabolism of Umeclidinium can be decreased when combined with Duloxetine.Approved
ValdecoxibDuloxetine may increase the antiplatelet activities of Valdecoxib.Investigational, Withdrawn
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Duloxetine.Approved, Investigational
ValsartanValsartan may increase the orthostatic hypotensive activities of Duloxetine.Approved, Investigational
VemurafenibThe serum concentration of Duloxetine can be increased when it is combined with Vemurafenib.Approved
VenlafaxineThe risk or severity of adverse effects can be increased when Venlafaxine is combined with Duloxetine.Approved
VerapamilVerapamil may increase the orthostatic hypotensive activities of Duloxetine.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Vigabatrin is combined with Duloxetine.Approved
VilazodoneThe risk or severity of adverse effects can be increased when Duloxetine is combined with Vilazodone.Approved
VinblastineThe metabolism of Vinblastine can be decreased when combined with Duloxetine.Approved
VinorelbineThe metabolism of Vinorelbine can be decreased when combined with Duloxetine.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Vortioxetine.Approved
WarfarinDuloxetine may increase the anticoagulant activities of Warfarin.Approved
XylazineDuloxetine may increase the tachycardic activities of Xylazine.Vet Approved
XylometazolineDuloxetine may decrease the antihypertensive activities of Xylometazoline.Approved
YM-178Duloxetine may increase the tachycardic activities of YM-178.Investigational
YohimbineThe metabolism of Yohimbine can be decreased when combined with Duloxetine.Approved, Vet Approved
ZalcitabineThe metabolism of Zalcitabine can be decreased when combined with Duloxetine.Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Duloxetine.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Ziconotide is combined with Duloxetine.Approved
ZimelidineDuloxetine may increase the serotonergic activities of Zimelidine.Withdrawn
ZiprasidoneThe metabolism of Duloxetine can be decreased when combined with Ziprasidone.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Zolazepam is combined with Duloxetine.Vet Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Duloxetine.Approved, Investigational
ZolpidemThe metabolism of Zolpidem can be decreased when combined with Duloxetine.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Duloxetine.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Duloxetine.Approved
ZotepineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Zotepine.Approved
ZuclopenthixolThe metabolism of Zuclopenthixol can be decreased when combined with Duloxetine.Approved, Investigational
Food Interactions
  • Food does not affect maximum levels reached, but delays it (from 6 to 10 hours) and total product exposure appears to be reduced by only 10%.
  • People taking this product who drink large amounts of alcohol are exposed to a higher risk of liver toxicity.
  • Take without regard to meals.
References
Synthesis Reference

Richard A. Berglund, “Intermediate useful for the asymmetric synthesis of duloxetine.” U.S. Patent US5491243, issued June, 1991.

US5491243
General References
  1. Turcotte JE, Debonnel G, de Montigny C, Hebert C, Blier P: Assessment of the serotonin and norepinephrine reuptake blocking properties of duloxetine in healthy subjects. Neuropsychopharmacology. 2001 May;24(5):511-21. [PubMed:11282251 ]
  2. Anttila S, Leinonen E: Duloxetine Eli Lilly. Curr Opin Investig Drugs. 2002 Aug;3(8):1217-21. [PubMed:12211418 ]
  3. Karpa KD, Cavanaugh JE, Lakoski JM: Duloxetine pharmacology: profile of a dual monoamine modulator. CNS Drug Rev. 2002 Winter;8(4):361-76. [PubMed:12481192 ]
  4. van Groeningen CJ, Peters GJ, Pinedo HM: Lack of effectiveness of combined 5-fluorouracil and leucovorin in patients with 5-fluorouracil-resistant advanced colorectal cancer. Eur J Cancer Clin Oncol. 1989 Jan;25(1):45-9. [PubMed:2784100 ]
  5. Jost W, Marsalek P: Duloxetine: mechanism of action at the lower urinary tract and Onuf's nucleus. Clin Auton Res. 2004 Aug;14(4):220-7. [PubMed:15316838 ]
  6. Carter NJ, McCormack PL: Duloxetine: a review of its use in the treatment of generalized anxiety disorder. CNS Drugs. 2009;23(6):523-41. doi: 10.2165/00023210-200923060-00006. [PubMed:19480470 ]
External Links
ATC CodesN06AX21
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelDownload (104 KB)
MSDSDownload (76.3 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9804
Caco-2 permeable+0.6358
P-glycoprotein substrateSubstrate0.7078
P-glycoprotein inhibitor IInhibitor0.5987
P-glycoprotein inhibitor IINon-inhibitor0.5519
Renal organic cation transporterInhibitor0.6525
CYP450 2C9 substrateNon-substrate0.5964
CYP450 2D6 substrateSubstrate0.6482
CYP450 3A4 substrateSubstrate0.5799
CYP450 1A2 substrateInhibitor0.839
CYP450 2C9 inhibitorNon-inhibitor0.7721
CYP450 2D6 inhibitorInhibitor0.6977
CYP450 2C19 inhibitorNon-inhibitor0.572
CYP450 3A4 inhibitorInhibitor0.5108
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.6689
Ames testNon AMES toxic0.5422
CarcinogenicityNon-carcinogens0.9293
BiodegradationNot ready biodegradable0.935
Rat acute toxicity2.5700 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Strong inhibitor0.5926
hERG inhibition (predictor II)Inhibitor0.6386
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Eli lilly and co
Packagers
Dosage forms
FormRouteStrength
Capsule, delayed releaseOral30 mg
Capsule, delayed releaseOral60 mg
Capsule, delayed releaseOral20 mg/1
Capsule, delayed releaseOral30 mg/1
Capsule, delayed releaseOral60 mg/1
Capsule, delayed release pelletsOral30 mg/1
Capsule, delayed release pelletsOral60 mg/1
Capsule, delayed release pelletsOral20 mg/1
Capsule, delayed releaseOral40 mg/1
Capsule, delayed releaseOral20 mg
Capsule, delayed releaseOral40 mg
Prices
Unit descriptionCostUnit
Cymbalta 30 mg Enteric Coated Capsule5.38USD capsule
Cymbalta 60 mg Enteric Coated Capsule5.38USD capsule
Cymbalta 30 mg capsule5.18USD capsule
Cymbalta 60 mg capsule5.18USD capsule
Cymbalta 20 mg Enteric Coated Capsule4.64USD capsule
Cymbalta 20 mg capsule4.62USD capsule
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2153856 No2005-05-102015-07-13Canada
CA2344057 No2008-11-182019-09-10Canada
US5023269 No1993-06-112013-06-11Us
US6596756 Yes2000-03-102020-03-10Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
logP4Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00296 mg/mLALOGPS
logP4.72ALOGPS
logP4.2ChemAxon
logS-5ALOGPS
pKa (Strongest Basic)9.7ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area21.26 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity87.73 m3·mol-1ChemAxon
Polarizability33.15 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as naphthalenes. These are compounds containing a naphthalene moiety, which consists of two fused benzene rings.
KingdomOrganic compounds
Super ClassBenzenoids
ClassNaphthalenes
Sub ClassNot Available
Direct ParentNaphthalenes
Alternative Parents
Substituents
  • Naphthalene
  • Aralkylamine
  • Alkyl aryl ether
  • Heteroaromatic compound
  • Thiophene
  • Organoheterocyclic compound
  • Secondary amine
  • Ether
  • Secondary aliphatic amine
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Serotonin:sodium symporter activity
Specific Function:
Serotonin transporter whose primary function in the central nervous system involves the regulation of serotonergic signaling via transport of serotonin molecules from the synaptic cleft back into the pre-synaptic terminal for re-utilization. Plays a key role in mediating regulation of the availability of serotonin to other receptors of serotonergic systems. Terminates the action of serotonin an...
Gene Name:
SLC6A4
Uniprot ID:
P31645
Molecular Weight:
70324.165 Da
References
  1. Chen F, Larsen MB, Sanchez C, Wiborg O: The S-enantiomer of R,S-citalopram, increases inhibitor binding to the human serotonin transporter by an allosteric mechanism. Comparison with other serotonin transporter inhibitors. Eur Neuropsychopharmacol. 2005 Mar;15(2):193-8. [PubMed:15695064 ]
  2. Troelsen KB, Nielsen EO, Mirza NR: Chronic treatment with duloxetine is necessary for an anxiolytic-like response in the mouse zero maze: the role of the serotonin transporter. Psychopharmacology (Berl). 2005 Oct;181(4):741-50. Epub 2005 Sep 29. [PubMed:16032412 ]
  3. Gould GG, Javors MA, Frazer A: Effect of chronic administration of duloxetine on serotonin and norepinephrine transporter binding sites in rat brain. Biol Psychiatry. 2007 Jan 15;61(2):210-5. Epub 2006 May 2. [PubMed:16650830 ]
  4. Mirza NR, Nielsen EO, Troelsen KB: Serotonin transporter density and anxiolytic-like effects of antidepressants in mice. Prog Neuropsychopharmacol Biol Psychiatry. 2007 May 9;31(4):858-66. Epub 2007 Jan 30. [PubMed:17335951 ]
  5. Vaishnavi SN, Nemeroff CB, Plott SJ, Rao SG, Kranzler J, Owens MJ: Milnacipran: a comparative analysis of human monoamine uptake and transporter binding affinity. Biol Psychiatry. 2004 Feb 1;55(3):320-2. [PubMed:14744476 ]
  6. Beique JC, Lavoie N, de Montigny C, Debonnel G: Affinities of venlafaxine and various reuptake inhibitors for the serotonin and norepinephrine transporters. Eur J Pharmacol. 1998 May 15;349(1):129-32. [PubMed:9669506 ]
  7. Karpa KD, Cavanaugh JE, Lakoski JM: Duloxetine pharmacology: profile of a dual monoamine modulator. CNS Drug Rev. 2002 Winter;8(4):361-76. [PubMed:12481192 ]
  8. van Groeningen CJ, Peters GJ, Pinedo HM: Lack of effectiveness of combined 5-fluorouracil and leucovorin in patients with 5-fluorouracil-resistant advanced colorectal cancer. Eur J Cancer Clin Oncol. 1989 Jan;25(1):45-9. [PubMed:2784100 ]
  9. Jost W, Marsalek P: Duloxetine: mechanism of action at the lower urinary tract and Onuf's nucleus. Clin Auton Res. 2004 Aug;14(4):220-7. [PubMed:15316838 ]
  10. Trivedi MH, Desaiah D, Ossanna MJ, Pritchett YL, Brannan SK, Detke MJ: Clinical evidence for serotonin and norepinephrine reuptake inhibition of duloxetine. Int Clin Psychopharmacol. 2008 May;23(3):161-9. doi: 10.1097/YIC.0b013e3282f41d7e. [PubMed:18408530 ]
  11. Bymaster FP, Lee TC, Knadler MP, Detke MJ, Iyengar S: The dual transporter inhibitor duloxetine: a review of its preclinical pharmacology, pharmacokinetic profile, and clinical results in depression. Curr Pharm Des. 2005;11(12):1475-93. [PubMed:15892657 ]
  12. Khullar V, Cardozo L, Dmochowski R: Mixed incontinence: current evidence and future perspectives. Neurourol Urodyn. 2010 Apr;29(4):618-22. doi: 10.1002/nau.20907. [PubMed:20432324 ]
  13. Carter NJ, McCormack PL: Duloxetine: a review of its use in the treatment of generalized anxiety disorder. CNS Drugs. 2009;23(6):523-41. doi: 10.2165/00023210-200923060-00006. [PubMed:19480470 ]
  14. Hunziker ME, Suehs BT, Bettinger TL, Crismon ML: Duloxetine hydrochloride: a new dual-acting medication for the treatment of major depressive disorder. Clin Ther. 2005 Aug;27(8):1126-43. [PubMed:16199241 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Norepinephrine:sodium symporter activity
Specific Function:
Amine transporter. Terminates the action of noradrenaline by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name:
SLC6A2
Uniprot ID:
P23975
Molecular Weight:
69331.42 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Gould GG, Javors MA, Frazer A: Effect of chronic administration of duloxetine on serotonin and norepinephrine transporter binding sites in rat brain. Biol Psychiatry. 2007 Jan 15;61(2):210-5. Epub 2006 May 2. [PubMed:16650830 ]
  3. Vaishnavi SN, Nemeroff CB, Plott SJ, Rao SG, Kranzler J, Owens MJ: Milnacipran: a comparative analysis of human monoamine uptake and transporter binding affinity. Biol Psychiatry. 2004 Feb 1;55(3):320-2. [PubMed:14744476 ]
  4. Beique JC, Lavoie N, de Montigny C, Debonnel G: Affinities of venlafaxine and various reuptake inhibitors for the serotonin and norepinephrine transporters. Eur J Pharmacol. 1998 May 15;349(1):129-32. [PubMed:9669506 ]
  5. Vincent S, Bieck PR, Garland EM, Loghin C, Bymaster FP, Black BK, Gonzales C, Potter WZ, Robertson D: Clinical assessment of norepinephrine transporter blockade through biochemical and pharmacological profiles. Circulation. 2004 Jun 29;109(25):3202-7. Epub 2004 Jun 7. [PubMed:15184278 ]
  6. Schou M, Halldin C, Pike VW, Mozley PD, Dobson D, Innis RB, Farde L, Hall H: Post-mortem human brain autoradiography of the norepinephrine transporter using (S,S)-[18F]FMeNER-D2. Eur Neuropsychopharmacol. 2005 Oct;15(5):517-20. Epub 2005 Apr 7. [PubMed:16139169 ]
  7. Mirza NR, Nielsen EO, Troelsen KB: Serotonin transporter density and anxiolytic-like effects of antidepressants in mice. Prog Neuropsychopharmacol Biol Psychiatry. 2007 May 9;31(4):858-66. Epub 2007 Jan 30. [PubMed:17335951 ]
  8. Karpa KD, Cavanaugh JE, Lakoski JM: Duloxetine pharmacology: profile of a dual monoamine modulator. CNS Drug Rev. 2002 Winter;8(4):361-76. [PubMed:12481192 ]
  9. van Groeningen CJ, Peters GJ, Pinedo HM: Lack of effectiveness of combined 5-fluorouracil and leucovorin in patients with 5-fluorouracil-resistant advanced colorectal cancer. Eur J Cancer Clin Oncol. 1989 Jan;25(1):45-9. [PubMed:2784100 ]
  10. Jost W, Marsalek P: Duloxetine: mechanism of action at the lower urinary tract and Onuf's nucleus. Clin Auton Res. 2004 Aug;14(4):220-7. [PubMed:15316838 ]
  11. Trivedi MH, Desaiah D, Ossanna MJ, Pritchett YL, Brannan SK, Detke MJ: Clinical evidence for serotonin and norepinephrine reuptake inhibition of duloxetine. Int Clin Psychopharmacol. 2008 May;23(3):161-9. doi: 10.1097/YIC.0b013e3282f41d7e. [PubMed:18408530 ]
  12. Bymaster FP, Lee TC, Knadler MP, Detke MJ, Iyengar S: The dual transporter inhibitor duloxetine: a review of its preclinical pharmacology, pharmacokinetic profile, and clinical results in depression. Curr Pharm Des. 2005;11(12):1475-93. [PubMed:15892657 ]
  13. Khullar V, Cardozo L, Dmochowski R: Mixed incontinence: current evidence and future perspectives. Neurourol Urodyn. 2010 Apr;29(4):618-22. doi: 10.1002/nau.20907. [PubMed:20432324 ]
  14. Carter NJ, McCormack PL: Duloxetine: a review of its use in the treatment of generalized anxiety disorder. CNS Drugs. 2009;23(6):523-41. doi: 10.2165/00023210-200923060-00006. [PubMed:19480470 ]
  15. Hunziker ME, Suehs BT, Bettinger TL, Crismon ML: Duloxetine hydrochloride: a new dual-acting medication for the treatment of major depressive disorder. Clin Ther. 2005 Aug;27(8):1126-43. [PubMed:16199241 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Monoamine transmembrane transporter activity
Specific Function:
Amine transporter. Terminates the action of dopamine by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name:
SLC6A3
Uniprot ID:
Q01959
Molecular Weight:
68494.255 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Carter NJ, McCormack PL: Duloxetine: a review of its use in the treatment of generalized anxiety disorder. CNS Drugs. 2009;23(6):523-41. doi: 10.2165/00023210-200923060-00006. [PubMed:19480470 ]
  4. Pereira P, Gianesini J, da Silva Barbosa C, Cassol GF, Von Borowski RG, Kahl VF, Cappelari SE, Picada JN: Neurobehavioral and genotoxic parameters of duloxetine in mice using the inhibitory avoidance task and comet assay as experimental models. Pharmacol Res. 2009 Jan;59(1):57-61. doi: 10.1016/j.phrs.2008.09.014. Epub 2008 Oct 5. [PubMed:18973814 ]
  5. Hunziker ME, Suehs BT, Bettinger TL, Crismon ML: Duloxetine hydrochloride: a new dual-acting medication for the treatment of major depressive disorder. Clin Ther. 2005 Aug;27(8):1126-43. [PubMed:16199241 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Knadler MP, Lobo E, Chappell J, Bergstrom R: Duloxetine: clinical pharmacokinetics and drug interactions. Clin Pharmacokinet. 2011 May;50(5):281-94. doi: 10.2165/11539240-000000000-00000. [PubMed:21366359 ]
  2. Lobo ED, Bergstrom RF, Reddy S, Quinlan T, Chappell J, Hong Q, Ring B, Knadler MP: In vitro and in vivo evaluations of cytochrome P450 1A2 interactions with duloxetine. Clin Pharmacokinet. 2008;47(3):191-202. [PubMed:18307373 ]
  3. Authors unspecified: Duloxetine: new indication. Depression and diabetic neuropathy: too many adverse effects. Prescrire Int. 2006 Oct;15(85):168-72. [PubMed:17121211 ]
  4. Carter NJ, McCormack PL: Duloxetine: a review of its use in the treatment of generalized anxiety disorder. CNS Drugs. 2009;23(6):523-41. doi: 10.2165/00023210-200923060-00006. [PubMed:19480470 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Knadler MP, Lobo E, Chappell J, Bergstrom R: Duloxetine: clinical pharmacokinetics and drug interactions. Clin Pharmacokinet. 2011 May;50(5):281-94. doi: 10.2165/11539240-000000000-00000. [PubMed:21366359 ]
  2. Preskorn SH, Nichols AI, Paul J, Patroneva AL, Helzner EC, Guico-Pabia CJ: Effect of desvenlafaxine on the cytochrome P450 2D6 enzyme system. J Psychiatr Pract. 2008 Nov;14(6):368-78. doi: 10.1097/01.pra.0000341891.43501.6b. [PubMed:19057238 ]
  3. Authors unspecified: Duloxetine: new indication. Depression and diabetic neuropathy: too many adverse effects. Prescrire Int. 2006 Oct;15(85):168-72. [PubMed:17121211 ]
  4. Carter NJ, McCormack PL: Duloxetine: a review of its use in the treatment of generalized anxiety disorder. CNS Drugs. 2009;23(6):523-41. doi: 10.2165/00023210-200923060-00006. [PubMed:19480470 ]
  5. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on December 02, 2016 03:58